312

THE REGISTRAR GENERAL'S STATISTICAL REVIEW OF ENGLAND AND WALES FOR THE YEAR 1953

SUPPLEMENT ON CANCER

BRITISH COUNCIL
-5 JAN 1959
MEDICAL LIBRARY

LONDON
HER MAJESTY'S STATIONERY OFFICE

Price 7*s.* 6*d.* net

THE REGISTRAR GENERAL'S
DECENNIAL SUPPLEMENT

ENGLAND AND WALES, 1951

OCCUPATIONAL MORTALITY
Part II

This report contains a detailed analysis based upon the deaths in the five years 1949–53 and the full Census results. The deaths have been analysed according to the occupation of the deceased (except for married women), and the death rates calculated on the basis of the 1951 Census populations by occupation. Deaths of married women have been analysed according to their husband's occupation.

The report contains tables showing, for most occupations separately, mortality by age and certain causes of death. The commentary volume analyses mortality according to the five broad occupational groupings traditionally known as the Registrar General's Social Classes and mortality from selected causes of death and in individual occupations. It also contains a study of infant mortality and stillbirths by the Social Class grouping of the parents.

Price £7. 7s. 0d. *net* the set of two volumes. *By post* £7. 9s. 0d.

Obtainable from
HER MAJESTY'S STATIONERY OFFICE
at the addresses shown on cover page iv
or through any bookseller



THE REGISTRAR GENERAL'S STATISTICAL REVIEW OF ENGLAND AND WALES FOR THE YEAR 1953

SUPPLEMENT ON CANCER

LONDON
HER MAJESTY'S STATIONERY OFFICE
1958

WELLCOME INSTITUTE LIBRARY
Coll. welMOmec
Call No. Ser QZ

TABLE OF CONTENTS

Page

History of the Cancer Records Scheme 1

Progress of Cancer Registration since 1945 1

Automatic Notification of Cancer Deaths 2

Scope of the Present Volume 4

Cancer of the Corpus Uteri 7

Cancer of the Ovary 11

Cancer of the Testis 14

Cancer of the Penis 16

Cancer of the Lip 18

Cancer of the Tongue 20

Cancer of the Mouth, Pharynx and Tonsil 23

Cancer of the Oesophagus 26

Sex Differences in Cancer of the Oro-pharynx and Oesophagus 28

Table 1. Cancer of various sites. Percentage distribution by age of (a) registration rates (1945-51) and (b) mortality rates (1946-50) per million population 31

Table 2. Cancer of various sites. Mortality in each of five years from start of treatment or, if untreated, registration date, by site and clinical stage; 1945-48 registrations 32

Table 3. Cancer of Corpus Uteri. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 34

Table 4. Cancer of Corpus Uteri. Relationship of age to clinical stage; 1945-51 registrations 35

Table 5. Cancer of Corpus Uteri. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 36

Page

Table 6. Cancer of Corpus Uteri. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 36

Table 7. Cancer of Corpus Uteri. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 37

Table 8. Cancer of Corpus Uteri. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 38

Table 9. Cancer of Corpus Uteri. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 39

Table 10. Cancer of Ovary. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 40

Table 11. Cancer of Ovary. Relationship of age to clinical stage; 1945-51 registrations 41

Table 12. Cancer of Ovary. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 41

Table 13. Cancer of Ovary. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 42

Table 14. Cancer of Ovary. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 43

Table 15. Cancer of Ovary. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 44

Page

Table 16. Cancer of Ovary. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 45

Table 17. Cancer of Testis. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 46

Table 18. Cancer of Testis. Relationship of age to clinical stage; 1945-51 registrations 47

Table 19. Cancer of Testis. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 48

Table 20. Cancer of Testis. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 48

Table 21. Cancer of Testis. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 49

Table 22. Cancer of Testis. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 50

Table 23. Cancer of Testis. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 51

Table 24. Cancer of Penis. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 52

Table 25. Cancer of Penis. Relationship of age to clinical stage; 1945-51 registrations 53

Table 26. Cancer of Penis. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 54

Page

Table 27. Cancer of Penis. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 54

Table 28. Cancer of Penis. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 55

Table 29. Cancer of Penis. Number and five-year survival rates, crude and corrected, of radically treated cases, by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 56

Table 30. Cancer of Penis. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 57

Table 31. Cancer of Lip. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 58

Table 32. Cancer of Lip. Relationship of age to clinical stage; 1945-51 registrations 59

Table 33. Cancer of Lip. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 60

Table 34. Cancer of Lip. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 61

Table 35. Cancer of Lip. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 62

Table 36. Cancer of Lip. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 63

Page

Table 37. Cancer of Lip. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 64

Table 38. Cancer of Tongue. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 65

Table 39. Cancer of Tongue. Relationship of age to clinical stage; 1945-51 registrations 66

Table 40. Cancer of Tongue. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 67

Table 41. Cancer of Tongue. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 68

Table 42. Cancer of Tongue. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 69

Table 43. Cancer of Tongue. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 70

Table 44. Cancer of Tongue. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 72

Table 45. Cancer of Mouth, Pharynx and Tonsil. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 74

Table 46. Cancer of Mouth, Pharynx and Tonsil. Relationship of age to clinical stage; 1945-51 registrations 76

Page

Table 47. Cancer of Mouth, Pharynx and Tonsil. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 77

Table 48. Cancer of Mouth, Pharynx and Tonsil. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 78

Table 49. Cancer of Mouth, Pharynx and Tonsil. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations. 80

Table 50. Cancer of Mouth, Pharynx and Tonsil. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 82

Table 51. Cancer of Mouth, Pharynx and Tonsil. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 84

Table 52. Cancer of Oesophagus. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations 85

Table 53. Cancer of Oesophagus. Relationship of age to clinical stage; 1945-51 registrations 86

Table 54. Cancer of Oesophagus. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations 87

Table 55. Cancer of Oesophagus. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations 87

Table 56. Cancer of Oesophagus. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations 88

Page

Table 57. Cancer of Oesophagus. Number and five-year survival rates, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations 89

Table 58. Cancer of Oesophagus. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations 90

Synoptic Table A 91

Synoptic Table B 92

Appendix Table. Condition at end of each year up to five years by site, sex, clinical stage and treatment; 1945-48 registrations 93

THE NATIONAL CANCER REGISTRATION SCHEME

History of the Cancer Records Scheme*

The first steps in the introduction of a scheme for recording cases of cancer on a national scale were taken by the Radium Commission, which, from 1930 until the National Health Service Act of 1948, controlled the supply of radium to Radiotherapy Centres. The collection of records from the centres was suspended during the war, because of the dispersal of many of the patients and shortage of clerical staff. In 1939 the Cancer Act required the council of every county and county borough to make, and submit for the approval of the Ministry of Health, arrangements for adequate facilities for treating cancer cases in their area. The Ministry advised the councils that, among other things, they should provide for the keeping of records, in a form which the Minister might approve, of treatment and its results, and should send copies to any person for the time being designated by the Minister. In 1944 the Ministry issued a circular letter to the authorities, together with specimens of Registration and Case Abstract cards which were prescribed as from October 1st, 1944, for use in all areas where a cancer scheme which had been approved by the Ministry was operating. At the end of the war the Radium Commission introduced a similar system of record cards in its radiotherapy centres. In June, 1945, the Commission was nominated temporarily as the Statistical Bureau for the collection and analysis of records, and this duty was taken over by the General Register Office in 1947. When the National Health Service Act came into force in July, 1948, the Cancer Act was repealed, and the continuation and extension of the plan for cancer records became the business of the Regional Hospital Boards and Boards of Governors.

Progress of Cancer Registration since 1945

In 1945, records were being received outside London from two regional cancer registries, most radiotherapy centres, and one gynaecological centre; and from one teaching hospital, two radiotherapy centres and four small hospitals in London.

In 1949, the Ministry of Health issued Circular R.H.B. (49)92/B.G.(49)77 urging the importance, in the development of facilities for the treatment of cancer, of accurate and full recording and follow up of all cases. The memorandum accompanying this circular referred to the need for every hospital region to have a regional cancer registry.

In 1954, the Ministry's Circular H.M.(54)18 again stressed the need for complete registration of all cases of cancer and invited

---

* This paragraph is reproduced from the General Register Office *Study on Medical and Population Subjects* No.3, Cancer Registration in England and Wales, (Stocks) 1950, H.M.S.O.

the co-operation of Regional Hospital Boards and Boards of Governors in this matter.

Since then the position has greatly improved and by 1957, eight regional hospital boards had set up regional organisations. These have had varying degrees of success in attaining complete registration, but all have shown a continual improvement. In five of these regions the registration rate has reached or passed 2.0 per thousand population.

By the beginning of 1958, another two regional boards had instituted a regional cancer registry, another was starting a pilot scheme as a preliminary to a regional organisation, and in two more there was reason to hope that regional registries would be started later in 1958.

During the past few years Boards of Governors of Teaching Hospitals have given excellent support to the National Cancer Registration Scheme, either collaborating with the Regional Hospital Boards in the creation and organisation of regional registries, or enabling records to be sent direct to the General Register Office. At the beginning of 1958, records were being provided by all London teaching hospitals, and all, except one, provincial teaching hospitals.

The table below provides a comparison of registrations in each hospital region in 1945, the first year for which records were sent to the General Register Office, and in 1953.

The registrations are also expressed as rates per thousand population to assist the comparison between the years and regions; these also give an indication of the completeness or otherwise of registration in each region. It is generally believed that registration of all hospital cases should produce a rate of at least 2.5 per thousand population for England and Wales as a whole.

Automatic Notification of Cancer Deaths

Since January, 1957, the General Register Office has been sending weekly to each of 8 hospital regions a copy of every death entry containing mention of cancer and registered in the region during the previous week.

In January, 1958, this service was extended to another 4 regions.

National Cancer Registration, 1945 and 1953

Hospital Region	Population (millions) (mid-1953)	Registrations			
		1945		1953	
		Number	Rate per thousand population	Number	Rate per thousand population
Newcastle	2.91	1,903	0.7	4,889	1.7
Leeds	3.04	2,583	0.8	3,937	1.3
Sheffield	4.17	2,737	0.7	5,012	1.2
East Anglia	1.46	895	0.6	2,384	1.6
Metropolitan:					
N.W.	3.87	794	0.2	5,817	1.5
N.E.	3.04	-	-	4,021	1.3
S.E.	3.20	4	-	3,497	1.1
S.W.	4.62	2,009	0.4	6,600	1.4
Oxford	1.46	279	0.2	3,478	2.4
South Western	2.77	1,613	0.6	6,261	2.3
Wales	*2.02	772	0.4	2,084	1.0
Birmingham	4.47	2,953	0.7	7,296	1.6
Manchester	4.37	4,048	0.9	4,931	1.1
Liverpool	*2.68	2,649	1.0	5,390	2.0
All Regions	44.08	23,239	0.5	65,597	1.5

* Adjusted to allow for part of North Wales which is covered by the Liverpool Cancer Registry.

SCOPE OF THE PRESENT VOLUME

In the present volume data from the National Cancer Registration Scheme relating to eight further cancer sites are presented. The sites discussed in the previous volume were:- in women the breast and cervix uteri, in men the prostate and in both sexes skin, lung, stomach, large intestine and rectum. The present sites comprise:- in women, corpus uteri and ovary, in men testis and penis and in both sexes lip, tongue, mouth and pharynx, and oesophagus. The pattern of tables and their discussion follow that already set and to facilitate comparisons at the various sites synoptic tables have been prepared summarising some of the most important numerical data for each of the sixteen sites.

In the present series data on incidence are drawn from registrations during the years 1945 to 1951, and on survival rates from registrations between 1945 and 1949. Only those cases registered prior to the commencement of specific treatment have been included since in the majority of cases registered after some form of treatment had been completed, or on the occasion of a recurrence, adequate details of conditions prior to treatment are not available.

The following definitions have been used:-

An Early growth is one "limited to the organ of origin," but for growths within the oral cavity an early growth is defined as one which has an estimated diameter of less than 4 cms. (Symbol: EP. Early Primary, i.e. early in stage, not in time).

Secondary Lymph Nodes are reported only when they have been detected on clinical examination. Their presence is denoted by the symbol $_S$ and their absence by $_O$. No distinction is made whether they are mobile or fixed, or present in one or more areas

Metastases refers to metastatic involvement elsewhere than in the lymphatic system.

The following stage groupings with their appropriate symbols have been used:-

EP_O, EP_S	An Early Growth with or without clinical involvement of lymphatic glands
LP_O, LP_S	A Late stage growth - (i.e. the original growth had extended to adjoining organs, or firm fixation had occurred; or in the case of the oral cavity the growth exceeded 4 cms. in diameter) - with or without clinical involvement of lymph glands
Met. or Metastatic spread.	Metastases were detected in organs other than lymph glands (irrespective of the stage of the primary growth)
Localised	refers to EP_O growths only
Regional spread	includes EP_S, LP_O and LP_S growths.

Survival rates are based on the number known to be alive at the end of the period, divided by the total number registered in the particular category under consideration, no allowance being made for untraced cases. Rates are wherever possible age-corrected for the probability, according to current life tables, of dying from other causes than cancer ($SR_{cor.}$). Where this is not appropriate, as in annual mortality following treatment, crude rates (SR_{cru}) are given.

The length of symptomatic history or "Duration" of the disease is the period between the patient's recollection of the date of the first symptom to the date of the commencement of treatment or, in untreated cases, the registration date.

A more complete account of the methods used in the collection of data and the calculation of rates is given in the *Supplements to the Statistical Review of England and Wales* for 1950-1951 and 1952* and in Study No.3, Cancer Registration in England and Wales†.

In the following tables the registration rates at different ages are compared and the proportion of cases in each clinical stage are shown. The relation between the length of the symptomatic history and the extent of the growth when treatment is commenced is examined, the median duration of symptoms for each clinical staging being shown.

Treatment is described as Radical or Palliative according as the intention was cure or alleviation of symptoms and classified as by Surgery or Radiotherapy alone or by a combination of both methods. The proportion in each clinical stage of cases so treated and of untreated cases is given.

Five-year survival rates are discussed in relation to the age of the patient, the stage of the disease and the length of history. The mortality in each of the successive years of the follow up period is compared.

Neither mortality rates nor registration rates can give a true pattern of the varying liability to cancer at different ages. The former take no account of the duration of the disease, nor of those cases which are cured or which die from some unrelated condition. The latter show the pattern of incidence among those cases only which attend hospital and ignore those in whom the disease is discovered at a stage too advanced for treatment or when death is imminent.

That the proportion of unregistered cases is highest at the older ages is shown by figures recently collected by the South Western Regional Cancer Records Bureau, and published in their Annual Report for 1954. During that year all death certificates

---

* *The Registrar General's Statistical Review of England and Wales*, for 1950-1951 - Supplement on General Morbidity, Cancer and Mental Health (1955), and for 1952 - Supplement on Cancer (1957), H.M.S.O.

† General Register Office: *Studies on Medical and Population Subjects*, No.3 - Cancer Registration in England and Wales (1950), H.M.S.O.

on which there was mention of cancer were examined and checked against the records of the Bureau. Two thirds of the unregistered cases were aged 70 years and over as compared with only one third of the registered cases. The proportion of unregistered cases varies from site to site and, until more data are available, it will not be possible to correct the registration rates sufficiently to obtain a reasonable estimate of the true incidence rate at individual sites.

The varying behaviour of cancer at different sites is well shown in the present series. For example, though both epithelioma of the lip and of the penis produce recognisable lesions at a very early stage and the median symptomatic history in each was six months, 77 per cent of the former, but only 43 per cent of the latter, were localised when registered. Though the median duration of growths of the tongue was but four months, only 40 per cent remained localised.

The proportion of cases where blood borne metastases are found varies also from site to site. Such metastases were found in two of every five ovarian cancers registered and in one out of every ten cancers of the corpus uteri and as few as one in one hundred and one in two hundred in the case of tongue and lip respectively. Except possibly in the case of epithelioma of the lip, the duration of symptoms bears little relation to the degree of extension of the disease at registration.

The survival rates when radical treatment is given depend mainly upon the clinical staging of the growth. The duration of the disease before the commencement of treatment has by comparison little effect upon the prognosis. At most of the sites discussed the five-year survival rate is better when symptoms have been present for more than six months than when the history is shorter. Among cancers of the tongue, mouth and pharynx and oesophagus the survival rates of women are considerably better than those of men treated in the same stage of the disease. This is discussed in some detail on a later page.

The crude rates of mortality from cancer at each individual site for each of the five years following registration or treatment are given. Where regional extension of the growth has taken place the mortality is invariably highest in the first year, after which it declines to a comparatively low figure in the fifth year. Among the localised growths which received radical treatment the picture is much less constant. In cancer of the tongue the second year mortality is appreciably higher than the first, falling abruptly in the third. In both cancer of the lip and of the penis the first year mortality is exceeded in subsequent years, but the year by year variation is comparatively small. The mortality from cancer of the oesophagus is very high in the first year and diminishes rapidly each succeeding year until the fourth. Finally, a brief note of the numbers and survivors among untreated cases is given.

CANCER OF THE CORPUS UTERI

Between 1945 and 1951, 3,749 women diagnosed as suffering from cancer of body of the uterus were registered under the National Cancer Registration Scheme. All were new cases in that none had received treatment for this condition prior to registration. 1,539 of these were registered before 1949, and have been followed up for five years.

Of the 3,749 registered between 1945 and 1951, in 58 per cent the stage of the primary growth at registration was described as "EP". That is, it was still confined to the uterus and had not invaded any adjoining tissue. In a further 32 per cent some degree of local extension beyond the uterine body had taken place. In the remaining 10 per cent [i.e. 370 cases] metastases to remote organs were present. In 349 of these metastatic cases the primary growth was in the Late stage, only 21 being associated with Early stage tumours. Secondary involvement of lymph nodes was recorded only in 145 cases, 37 of these being associated Early growths and amounting to only 1.6 per cent of all cases where the primary growth was staged as "Early".

Diagram A



Cancer of Corpus Uteri. Percentage distribution by age, of registration rates (1945-51) and mortality rates (1951-55) per million population.

In the following analysis staging will be restricted to three groups, either "Early" or "Late" (whether local extension had not or had occurred), irrespective of whether secondary glandular involvement had been observed clinically, and "metastatic" where the presence of metastases to distant organs had been diagnosed.

Incidence

The mean age of all cases registered was 60.1 years (some five years older than those registered with cancer of the cervix uteri - see Registrar General's Supplement to the Statistical Review for 1950-51). Of those with an Early growth it was 59.2 years, among those with a Late growth 61.8 years while among those with metastases it was 60.2 years.

Very few cases were registered under the age of 35, thereafter the registration rate (number registered per million of population at risk) rose rapidly until the age group 55-59. After the age group 60-64 the registration rate fell rapidly. Mortality, based on the 1951-55 experience, behaved quite differently; the death rate from cancer of the corpus uteri rose after the age group 45-49 very steadily until the final age group 80-84. (Tables 1 and 3).

Among those registered before the age of 45 years the proportion with Early growths was 67 per cent, with Late growths 22 per cent and with metastatic spread 12 per cent. The proportions in the next age group 45-49 were similar but thereafter the Early cases diminish in each succeeding age group while the Late cases increase until in the age group 75-79 the Early cases amount to 52 per cent and the Late cases 37 per cent. The proportion of cases in whom metastases are found at registration does not materially change with age. (Table 4).

Length of symptomatic history appears to influence the clinical staging of tumours less than age. Among those whose symptoms had been present for less than six months the proportion of Early cases was 62 per cent, among those with symptoms lasting between six months and twelve months 58 per cent and among those who gave a history of one year or more 56 per cent. The median duration of all Early cases was 7.1 months, that of the Late cases 8.1 months and of those with metastases 7.6 months. Scarcely more than one tenth of all cases were registered within two months of the appearance of symptoms and more than a third of all cases gave a history of one year or more. (Table 5).

Surgical treatment either alone or in combination with radiotherapy was the more frequent mode of treatment at all stages of the disease. Among the Early cases treatment described as radical was given in 96 per cent of cases, in 47 per cent surgery alone was used and in 23 per cent surgery combined with radiotherapy. Radical treatment was found possible in 69 per cent of Late cases, but only 21 per cent were treated by surgery alone and 15 per cent with radiotherapy in addition. 46 per cent of the Late cases, but only

27 per cent of the Early ones, received radiotherapy as the sole form of treatment. (Table 6).

Surgery tended to be used more frequently in younger than in older women. Only one third of those staged as Early and treated by radiotherapy alone were under the age of 60 years, but of those treated solely by surgery the proportion was two thirds. (Table 7).

Survival

The crude five-year survival rate for all registered cases (1,539), irrespective of stage or type of treatment administered was 44 per cent. For the 1,531 cases whose ages were known the age corrected survival rate was 49 per cent. Among those Early cases which received radical treatment the corrected five-year survival rate was 67 per cent (crude - 61 per cent) while for Late cases receiving a radical form of treatment it was 46 per cent (crude - 41 per cent). (Table 8).

Of the patients whose age was known 91 were under the age of 45 years and among these the five-year survival rate, corrected for age, was 56 per cent. There were 125 cases in the age group 45-49 with a corrected survival rate of 67 per cent. In each succeeding age group the corrected survival rate fell reaching 29 per cent for women aged 70 years and over.

Similar fluctuations of the rate with age were found among the Early and radically treated cases where under the age of 45 the corrected survival rate was 70 per cent, rising to 88 per cent in the next age group and falling to 41 per cent in the age group 70-74.

A shorter symptomatic history was not associated with an improved survival rate. For all cases registered, the five-year crude survival rate increased from 35 per cent for those registered within two months of the appearance of symptoms, to 49 per cent where symptoms had persisted for more than twelve months. Among Early cases receiving radical treatment, the crude survival rate for 315 cases with a history of less than six months was 56 per cent, while for the 452 whose history exceeded six months it was 64 per cent. (Table 9).

Among those with Early growths older women tended to give a shorter history than younger. The median duration of symptoms in cases with Early growths fell from 10.5 months in women aged 35 to 44 to 6.5 months in women aged 70 to 79. Despite this, the age corrected survival rate fell from 88 per cent in the 45-49 age group to 44 per cent in the oldest group, suggesting that on average the malignancy of these tumours increases with increasing age.

Early cases radically treated

Age group	35-	45-	50-	55-	60-	70-79
*Median duration of Symptoms	10.5	10.0	8.5	8.3	6.6	6.5
Corrected Survival Rate	70%	88%	78%	73%	62%	44%

Among Early cases receiving radical treatment mortality fell from about 11 per cent in the first two years of follow up to about 6 per cent in the last two years. In the Late cases the mortality in the first two years was high, 38 per cent and 28 per cent, but fell to 13 per cent in the third year and 10 per cent in each of the two following years. (Table 2).

Of 15 Early cases which received no treatment, 3 were known to be alive five years later, only 3 cases being untraced; while of 79 Late cases but 3 were alive five years later, 5 cases being untraced.

CANCER OF THE OVARY

Incidence

Malignant ovarian tumours accounted for 4,525 registrations between 1945 and 1951. In only 22 per cent of these was the growth confined to the ovary itself. In 40 per cent local extension to adjoining organs was diagnosed clinically and in the remaining 38 per cent metastases were discovered in remote organs. (Table 11).

The mean age of all registered cases was 54.5 years. That of the Early cases where no extension of growth had occurred was 51.8 years. The mean age of later cases and those in whom metastases had been detected was 55.3 years in both groups.

62 cases of cancer of the ovary were reported in women and children under the age of 25 years (9 of whom were under 15). Above this age the registration rate rose rapidly to a peak in the age group 50-54 and remained high until the age group 65-69, after which it fell rapidly. In contrast the rate of mortality (1946-50) increased more slowly up to the age group 55-59 with a small secondary rise in the age group 65-79. The curves of registration rates from both cancer of the corpus uteri and ovary are thus in

Diagram B



Cancer of Ovary. Percentage distribution by age, of registration rates (1945–51) and mortality rates (1946–50) per million population.

general shape similar, but the curves of mortality differ fundamentally. Mortality from cancer of the corpus uteri increases throughout life but liability to death from ovarian cancer changes little after about the age of 55. (Tables 1 and 10).

Below the age of 30 years 47 per cent of cases were diagnosed before local extension had occurred. Above this age the proportion of Early cases decreased until between the ages of 75 and 79 it was only 14.5 per cent. Neither the proportion of Late cases, nor those showing metastatic spread showed so constant a relation to age. (Table 11).

The median recorded duration of all registered cases was 4.4 months and that of the Early cases was the same, while those of Late and Metastatic cases were 4.5 and 4.2 months, respectively. (Table 12).

Approximately one fifth of the cases were registered within two months of recognising the first symptom and in nearly 27 per cent of those the growth was recorded as Early. A slightly smaller number gave a symptomatic history of more than one year and in 26 per cent of these Early growths were found. Among the remaining three fifths with a recorded history between two and twelve months the proportion of Early growths slightly exceeded 20 per cent.

Surgery, either alone or combined with radiotherapy, was used in 95 per cent of Early cases. (In all but 4 per cent treatment was described as radical). Among Late cases the percentage was 53, radiotherapy alone being used in 18 per cent and 30 per cent receiving no treatment. Among those with metastases at registration 55 per cent were not treated. (Table 13).

Survival

The five-year crude survival rate of the 1,824 cases of known age registered between 1945 and 1948, was 17 per cent. Corrected for age it was 18 per cent. Both rates were much higher among those below the age of 45 when the corrected rate was 27 per cent while above that age it averaged 16 per cent. (Table 15).

Of 333 cases which received radical treatment to an Early stage growth, 175 survived five years, giving a corrected survival rate of 57 per cent. Among these cases the corrected survival rate shows no regular change with age, the highest survival rates being found in those aged around 30 and 60 years. Among 294 Late cases radically treated the corrected survival rate was 30 per cent, the survival rate for all Late cases being 15 per cent.

The length of symptomatic history had little effect upon the survival rates. Among Early cases radically treated the crude five-year survival rate was 52 per cent when a history of less than 6 months was given and 57 per cent for longer periods. (Table 16).

Mortality among the Early cases which received radical treatment was heaviest in the first year after operation when it amounted to 19 per cent. For the next three years it averaged 10 per cent,

falling to 4 per cent in the fifth year. Since only about one tenth of the deaths recorded in the first year occurred within the first six weeks, post operative mortality was not unduly high and cannot account for the high first year mortality. Among Late cases mortality fell from 67 per cent in the first year to 9 per cent in the fifth. (Table 2).

247 Late cases received no treatment, 6 of which were still alive at the end of five years and 4 were untraced. Of 428 cases in which metastases were diagnosed, 4 survived the five year period and 5 were untraced.

CANCER OF THE TESTIS

Incidence

Between 1945 and 1951, registrations of previously untreated cancer of the testis amounted to 847. The average age in this group was 40.3 years, 62.3 per cent of cases falling between the ages of 25 and 44 years. 29 per cent were aged 45 years and over and 8 per cent were below the age of 25 years. 8 cases were recorded below the age of 5 years. The peak of the registration rate occurred in the age group 35-39 years, following which it fell rapidly until 65-69 years, rising again up to a lower peak in the 75-79 age group. (Tables 1 and 17).

In more than half the cases registered the growth was localised in the testis, without evidence of glandular involvement or remote metastases. Glandular involvement was relatively uncommon, being found in but 14 per cent of all cases, while distant metastases were recorded in 16 per cent. (Table 18).

Metastatic spread appeared more frequently in the younger age groups, where it was diagnosed in 24 per cent of those aged 15 to 29 years, compared with about 14 per cent at older age groups. The

Diagram C



Cancer of Testis. Percentage distribution by age, of registration rates (1945-51) and mortality rates (1946-50) per million population.

proportion of completely localised growths showed no regular trend with age, though the proportion registered fell from 65 years onwards.

Of those registered while the growth was still localised, in 58 per cent symptoms had been present for less than six months, the median duration being 4.9 months. Where local, glandular or metastatic extension had occurred, the median duration was about a month longer. About 62 per cent of all cases registered within six months of the appearance of symptoms had completely localised or EP_0 stage growths, while of those with longer history the percentage was 54. Even when symptoms had been present for upwards of one year more than half were found to have EP_0 stage growths. (Table 19).

Surgery was used in the majority of cases, generally in combination with radiotherapy, 80 per cent of EP_0 stage growths being treated by the combined method and a further 17 per cent by radical surgery alone. (Table 20).

Survival

For 350 cases registered between 1945 and 1948, and followed up for 5 years, the corrected five-year survival rate was 52 per cent. Of these 193, staged as EP_0, received radical treatment, of which 138 were known to be alive five years later, giving a corrected survival rate of 74 per cent. In a similarly treated group of 68 cases in which local or glandular extension of growth had occurred, the corrected survival rate was 41 per cent. (Table 22).

When symptoms had been present for less than six months, the crude survival rates of Early cases which received radical treatment (about 8 per cent) were slightly better than when symptoms were present for longer periods, but no real trend in survival rates with a lengthening symptomatic history could be detected. (Table 23).

Mortality among those with cancer of the testis was high during the first two years following registration and low during the three succeeding years. For the whole series of 352 cases mortality fell from 35 per cent in the first year to 13 per cent in the second and 3 per cent in each of the two succeeding years to 1 per cent in the fifth. Among the 195 radically treated EP_0 cases only 40 out of the 47 known deaths occurred in the first two years, while among the 89 cases with regional involvement 52 out of 57 deaths occurred in the first two years and none in the final year. (Table 2).

Of 24 untreated cases only 1 case, which had been staged as EP_0, was alive at the end of five years, while 1 case was untraced.

CANCER OF THE PENIS

Incidence

The series consists of 1,086 previously untreated cases of cancer of the penis registered between 1945 and 1951, of whom 537 registered before 1949 were followed up for five years. The mean age of all registered cases was 64.5 years, only 1 case being registered below the age of 30 years. After the fourth decade the registration rate rose more gradually than the mortality rate to the final age group of 85 and over. (Tables 1 and 24).

In 43 per cent of cases registered the growth was confined to the penis and no glandular or other metastatic spread could be detected. Distant metastases were rare, being found in only 2 per cent of all cases, while local glandular involvement was found in 44 per cent cases. (Table 25).

Below the age of 75 years the proportion of Early cases (EP_0) did not vary with age, but a higher proportion of cases where both local extension and glandular involvement had occurred were found among older men.

Length of symptomatic history did not appear to affect the staging of the growth. For all registered cases the median duration of symptoms was 6.0 months. Approximately the same figure

Diagram D



Cancer of Penis. Percentage distribution by age, of registration rates (1945–51) and mortality rates (1946–50) per million population.

was found for each clinical stage, except where metastases were present; here, among 18 cases the median duration exceeded seven months. (Table 26).

Treatment was most often surgical, radiotherapy being used as an adjunct in a proportion of cases. Radiotherapy alone was more frequently used in EP_0 cases and less often where local or other spread had occurred. Thus 28 per cent of EP_0 cases, but only 21 per cent of later cases, were treated by radiotherapy. (Table 27).

Survival

Survival rates were less affected by staging than cancer at most other sites. The corrected survival rate for the whole series of 537 cases was 55 per cent, that of the earliest clinical stage (EP_0) being 71 per cent, while those for the two succeeding stages where either local (LP_0) or glandular (EP_S) spread had occurred were 67 per cent and 65 per cent respectively. (Table 29).

Under the age of 80 years, survival was independent of age, whatever the clinical stage of the growth, but among the 34 cases aged 80 years and over the corrected survival rate was only 24 per cent.

No constant relation between length of history and survival could be demonstrated. At all Early stages of growth the survival rate was a little higher among those with a history exceeding six months, but the difference was relatively unimportant. (Table 30).

Among the radically treated EP_0 cases mortality rose slightly in each of the first three years following treatment, from 10 per cent in the first year to 12 per cent in the third. Thereafter, it fell to 9 per cent in the fourth and 6 per cent in the fifth year. (Table 2).

Mortality among those in whom regional extension had occurred fell from 28 per cent in the first year to the low figure of 4 per cent in the fourth year, but rose to 10 per cent in the fifth year.

20 untreated EP_0 cases were registered, of whom 5 were known to be alive at the end of five years, 9 cases being untraced. Of 33 untreated cases with regional extension only 2 were known to be alive and 3 were untraced.

CANCER OF THE LIP

Incidence

Between 1945 and 1951, 4,050 cases of cancer of the lip were registered, of which there were 3,724 men and 326 women, a male/female ratio of 11.4 : 1. Although this condition is so much more frequent in men than in women, analysis shows that, as far as these records are concerned, the course of the disease is not appreciably different in the two sexes. Thus the percentage of Early primary cases without clinical evidence of glandular involvement was 77 in men and 80 in women. The median durations of symptoms in these cases were 6 months and 5.7 months, while the corrected five-year survival rates were 88 per cent and 90 per cent for men and women, respectively. The age distribution of the lesion was similar in both sexes, the mean age at registration in men being 65.6 years and in women 66.0 years; while 12 per cent of the men were registered under the age of 50 years, compared with 13 per cent of women. (Tables 33 and 1).

Metastatic spread is not common in cancer of the lip. Glandular involvement was seen in 17 per cent of cases, while distant metastases were recorded in less than half of one per cent. The proportion registered after invasion of glands or extensive local spread had taken place tended to rise with age, the proportion

Diagram E



Cancer of Lip. Percentage distribution by age, of registration rates (1945–51) and mortality rates (1946–50) per million population.

of EP_0 cases falling from about 84 per cent below the age of 55 to 70 per cent between 75 and 84 years and 58 per cent for still older ages. The proportion of more advanced cases rose also with the patient's account of the duration of the lesion, from 15 per cent of all cases, when the history was less than two months, to 27 per cent, when it exceeded twelve months. (Table 32).

More than four fifths of Early cases were treated solely by radiotherapy, surgery alone being used in but 7 per cent of these cases. Surgery combined with radiotherapy was the chosen form of treatment in 8 per cent of the Early cases, but in 17 per cent of the later ones. (Table 34).

Survival

Survival rates from cancer of the lip are high. The age corrected five-year survival rate for 1,957 cases registered between 1945 and 1948, was 78 per cent. In 1,443 cases in the Early stage and showing no signs of glandular involvement, radical treatment produced a corrected survival rate of 88 per cent. (Table 36).

Among 372 cases with more extensive growths, which were given radical treatment, the corrected survival rate was 63 per cent. The remaining 142 cases, consisting of those which received palliative treatment or which for various reasons were untreated, had a corrected survival rate of 18 per cent.

Between the ages of 45 and 74 years the survival rates were in general high and showed little variation with age, the corrected survival rate of Early cases which received radical treatment exceeding 90 per cent. At ages both younger and older than this the rates were lower, averaging 77 per cent both for those under 45 years of age and those aged 75 years and more.

Crude survival rates were slightly better, especially among Early cases, when the duration of the disease was six or more months than for shorter periods. (Table 37).

Among the EP_0 group, which received radical treatment, mortality varied comparatively little during each of the five years of follow up. The highest mortality (8 per cent) was recorded in the second year. (Table 2).

43 cases were untreated and of these 5 were known to be alive five years after registration and 5 were untraced.

CANCER OF THE TONGUE

Incidence

There were 4,188 cases of cancer of the tongue registered between 1945 and 1951. Of these 3,185 were in men and 1,003 in women.

The mean age at registration was 68.3 years in men and 64.9 years in women. The registration rates pointed to an increasing incidence of this form of cancer from the end of the third decade up to the age of 75-79. In this they follow a similar course to the mortality rates, though in the latter the increase continued up to the age group 80-84 years. (Tables 1 and 38).

The proportion of cases registered while the growth was still confined to the tongue without clinical evidence of glandular involvement or remote metastases was lower in men than women. In men, only one third of growths were so localised, while in women the proportion was 53 per cent. Metastases to remote organs were uncommon and seen only in about 1 per cent of cases, though when the original growth had spread beyond the true substance of the tongue, invaded lymph glands were recorded in more than two thirds of cases. (Table 39).

Diagram F



Cancer of Tongue. Percentage distribution by age, of registration rates (1945-51) and mortality rates (1946-50) per million population.

Although a higher proportion of women than men was registered while the growth was in an Early stage and completely localised within the tongue, the median symptomatic history recorded was nearly one month longer for women than for men (men 3.7 months; women 4.5 months). 68 per cent of men gave a history of less than six months while for women the figure was 59 per cent. In both sexes a slightly higher proportion of EP_0 cases were found among those with a symptomatic history of less than two months, but for any longer period staging appeared to be independent of the duration of symptoms. Among those with less than two months history 40 per cent of men and 61 per cent of women were recorded as having EP_0 stage growths, while among those whose history exceeded two months 32 per cent of men and 53 per cent of women were so recorded. (Table 40).

In the treatment of Early cases without glandular involvement radiotherapy alone was the method of choice in about 70 per cent of cases. In a further 20 per cent it was combined with surgery, only about 8 per cent being treated by surgery alone. If glandular invasion had occurred the proportion of cases treated by surgery and radiotherapy combined rose to 34 per cent. In the remaining stages surgery was employed much less frequently. (Table 41).

Survival

Five-year survival rates are considerably higher in women than in men. The corrected survival rate of 241 women registered in the Early non invasive stage was 57 per cent, while that of 532 men was 47 per cent. The corrected survival rates for the whole series were 38 per cent for women and 22 per cent for men. (Table 43).

There was less variation with age in the corrected survival rate for women, though in both sexes the rate tended to be lower for those aged 65 years and over. Among the EP_0 stage growths the corrected survival rates for those aged 65 and over were 43 per cent and 54 per cent for men and women, respectively, while for the younger group they were 54 per cent and 61 per cent, respectively.

Among those men who received radical treatment for an Early (EP_0) stage growth the survival rate did not appreciably vary with the length of history if the latter was less than one year. A much higher survival rate was, however, recorded among those who gave a history of a year or more. Among 442 men where the duration of symptoms was less than 12 months the survival rate was 32 per cent, while among 74 men who gave a history of one year or more it was 53 per cent.

Among 229 women with Early growths (EP_0) who received radical treatment the highest survival rate (59 per cent) was among those treated within two months of its apparent onset. As the interval increased the survival rate fell to 47 per cent for those with a history from two to six months and 37 per cent for those where it was more than six months and less than one year. For longer

periods, however, it was again high; 40 women gave a history of one year or more and of these exactly half were known to be alive five years later. (Table 44).

Among Early (EP_0) cases who received radical treatment mortalit was highest during the first two years, being slightly higher in bot sexes in the second than in the first. In the third year it fell considerably to about one half of that in each of the two preceding years, diminishing only slightly in the two final years. (Table 2).

Of 266 untreated cases, 3 cases, 2 of which had been staged EP_0 were known to be alive five years after registration, 25 being untraced.

CANCER OF THE MOUTH, PHARYNX AND TONSIL

Under this head are included all malignant neoplasms classified to I.S.C. Nos. 142-148; that is, all malignant growths of the salivary glands, mouth, tonsil, nasopharynx and hypopharynx.

Incidence

Between 1945 and 1951, 12,157 registrations of previously untreated cases were recorded. 8,375 were in men and 3,782 in women. The average age of the men was 66.2 years and of the women 59.8 years. In women both the registration rate and the mortality rate began to rise nearly a decade earlier than in men, the registration rate reaching a peak in the age group 70-74 years, whereas in men it rose until the age group 75-79. The curve of mortality below the age group 70-74 is less steep in women than in men but beyond that age group there is little difference. Below the age of 55 the male to female ratio of registrations was near to unity (M. 1,337 : F. 1,239) but from that age onwards the ratio was 2.78 : 1. (Tables 1 and 45).

The proportion of Early cases (EP_0) among men was markedly lower (26 per cent) than among women (34 per cent); this was found at each age group. In both sexes the proportion of Early cases

Diagram G



Cancer of Mouth, Pharynx and Tonsil. Percentage distribution by age, of registration rates (1945-51) and mortality rates (1946-50) per million population.

tended to fall as age increased. Metastatic spread was not common and amounted to 2.2 per cent in both sexes. Glandular involvement was found in 52 per cent of men compared with only 36 per cent of women. (Table 46).

Despite the higher proportion of Early cases seen, women tended to delay longer in seeking treatment than men. Under 7 per cent of women were registered with a symptomatic history of less than two months, while more than 13 per cent of men gave a similar history. 64 per cent of the men gave a history of less than six months symptoms, but only 46 per cent of the women; while in 30 per cent of women, compared with 17 of men, the growth had been present for more than a year. Among 1,203 women who were registered in the EP_0 stage the median duration of symptoms was 8.8 months, while in 2,066 men it was 4.5 months. In neither sex was length of symptomatic history correllated with the stage of the growth at registration; in both sexes a shorter history was recorded when glandular extension had occurred than when it was absent. (Table 47).

Radical radiotherapy alone was more frequently the treatment of choice in men than in women. Among the EP_0 group 63 per cent of men received radiotherapy while in a further 20 per cent surgery was used in addition. In women only 47 per cent were treated by radical radiotherapy alone and in 24 per cent surgery and radiotherapy were combined. Surgery, either alone or together with radiotherapy, was much less frequently used in any of the later stages. (Table 48).

Survival

The corrected survival rates for all cases were 23 per cent for men and 32 per cent for women. For the Early cases without glandular enlargement the rates were 51 per cent and 65 per cent for men and women, respectively. Up to the age of 64 the corrected survival rates in this group were much the same in either sex (60 per cent and 63 per cent, respectively), but from 65 years onwards the male rates tended to fall with each increase in age, while in women no such trend is seen. The corrected survival rates for ages 65 years and more were 44 per cent for men and 70 per cent for women. (Table 50).

For all stages of growth and in both sexes the crude survival rates were notably higher when the symptomatic history exceeded twelve months. For periods less than one year there was little significant difference in the survival rates, whatever the length of history. (Table 51).

Mortality following the radical treatment of localised growths showed a different pattern in men than in women. During the first year there was little difference, but whereas in women it fell rapidly in the three subsequent years with a slight rise in the final year, in men the mortality in the second year exceeded that

in the first, falling only in the three final years.

Mortality in	Males	Females
1st year	19.8	20.3
2nd year	22.9	10.5
3rd year	15.7	7.1
4th year	12.0	1.3
5th year	8.0	4.7

No treatment was recorded for 55 cases staged as EP_0. Of these 5 out of 31 men and 6 out of 24 women were still alive five years later. 11 men and 3 women were untraced. Among the more advanced stages 655 cases were untreated, of whom 3 men out of 454 and 5 women out of 201 were alive five years later, 38 men and 20 women being untraced.

CANCER OF THE OESOPHAGUS

Incidence

Between 1945 and 1951, oesophageal cancer accounted for 4,470 registrations. There were 3,088 cases among men and 1,382 among women, a male to female ratio of 2.2 : 1.

In both sexes the disease was rare below the age of 40 years, but thereafter the registration rates increased rapidly up to the age group 70-74 in women and 75-79 in men, falling considerably in subsequent age groups. The average age of men registered was 66.3 years and of women 63.7 years. (Tables 1 and 52).

The proportion of cases registered in a clinically Early stage (EP_0) was low in both men and women (15 per cent and 19 per cent, respectively), but metastatic spread was found in only about 8 per cent of all cases (men: 8.5 per cent; women: 6.6 per cent). In each age group a slightly higher proportion of women than men was registered while the growth was still in an Early stage and in both sexes after the age of 45 years the proportion of Early stage growths tended to fall with increasing age. (Table 53).

The delay between the onset of symptoms and registration was longer in women than in men, the median duration being 4.0 months in men and 4.9 months in women. More than 70 per cent of men,

Diagram H



Cancer of Oesophagus. Percentage distribution by age, of registration rates (1945-51) and mortality rates (1946-50) per million population.

but only 61 per cent of women were registered with less than a six months history. Among those registered in an Early stage the median duration of symptoms was for men slightly shorter than that for the whole series and slightly longer in the case of women. (Table 54).

Radical treatment was given in only two thirds of those registered with an EP_0 stage growth and 15 per cent of this group for various reasons received no treatment. Of the 478 Early cases given radical treatment 55 per cent were treated surgically, 39 per cent by radiotherapy alone and 5 per cent by a combination of these methods. In the whole series the proportion of untreated cases was high amounting to 39 per cent of all registered cases. (Table 55).

Survival

Of the 2,191 cases followed up for five years after registration, only 36 were known to be alive at the end of the period. Of 139 Early cases among men who received treatment described as radical 8 were alive five years later, giving a five-year corrected survival rate of 7 per cent. Of 77 women in the Early stage who received radical treatment 11 remained alive giving a corrected survival rate of 15 per cent. Of the whole series of 1,537 men 17 remained alive, the corrected survival rate being 1.4 per cent, while of the 654 women 19 remained alive, giving a corrected survival rate of 3.2 per cent.

Post operative mortality among the EP_0 cases which received radical treatment was high, 15 per cent of all deaths occurring within the first ten days and 25 per cent within the first fifty days. The annual mortality fell from 63 per cent in the first year to 8 per cent in the fourth and 10 per cent in the fifth year. Of the 24 cases surviving three years only 2 died in each of the two following years.

Of 823 cases which received no treatment only 1 survived the five-year period, 36 being untraced.

SEX DIFFERENCES IN CANCER OF THE ORO-PHARYNX AND OESOPHAGUS

Men are much more liable than women to cancer of the upper digestive tract. The difference is greatest at the lip where the ratio of cases registered was 11.4 males to each female. Three and one fifth times as many men as women were registered with cancer of the tongue and two and one fifth times as many men with cancer of mouth, tonsil and pharynx or oesophagus.

Despite the pronounced sex difference in incidence cancer of the lip behaves in a similar manner in both sexes. There is no significant difference between either the stage distribution of the disease at registration or the mean duration of symptoms, while the five-year survival rates are practically identical.

At the remaining sites the course of cancer shows considerable differences between men and women. At each site the mean age at registration is higher in men, the difference amounting to as much as 6.4 years in cancer of the mouth and pharynx where only 40 per cent of women were aged 65 years and upwards, compared with 62 per cent of men. The differences for cancer of the tongue and oesophagus are 3½ and 2½ years, respectively.

Women on average give a longer history than men especially in regard to Early growths. The validity of such statements as the duration of a symptom are difficult to assess, depending as they do both on accuracy of memory and acuteness of perception, but the differences here are frequently considerable and merit serious consideration.

Median duration of symptoms (months)

	EP_0 cases		All cases	
	Male	Female	Male	Female
Lip	6.0	5.7	6.4	6.1
Tongue	3.7	4.5	3.9	4.6
Mouth etc.	4.5	8.8	4.3	6.7
Oesophagus	3.8	5.0	4.0	4.9

Despite the longer history given by women at each site, except lip, they recorded a larger proportion of Early cases.

Percentage of EP_0 cases registered

	Male	Female
Lip	76.8	80.1
Tongue	32.5	53.5
Mouth etc.	26.3	34.1
Oesophagus	14.7	18.7

In the five-year corrected survival rates (again with the exception of lip) women have a considerable advantage, whatever the clinical stage of the disease.

Five-year corrected survival rates

	EP_0 cases (radical treatment)		All cases	
	Male	Female	Male	Female
Lip	88	90	79	73
Tongue	47	57	22	38
Mouth etc.	51	65	23	32
Oesophagus	7	15	1	3

Thus it would seem that cancer of the tongue, mouth, pharynx and oesophagus assumes a more malignant form in men than in women. In women it appears to grow at a slower rate, since the median symptomatic history at corresponding clinical stages is on average longer. That it is in general of less highly invasive type is shown by the higher proportion of cases registered among women where the growth had neither spread to neighbouring tissues nor produced glandular or other metastases. Finally, the corrected survival rates, whether the disease has remained localised or not, are considerably higher among women than among men.

Table I. Cancer of various sites. Percentage distribution by age of (a) registration rates (1945–51) and (b) mortality rates (1946–50*) per million population

Age Group	Corpus Uteri		Ovary		Testis		Penis		Lip				Tongue				Mouth, Pharynx and Tonsil				Oesophagus			
									Males		Females		Males		Females		Males		Females		Males		Females	
	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)	(a)	(b)
15–24	–	–	0.6	0.2	3.4	4.1	–	–	–	–	–	–	–	–	–	–	0.1	0.1	0.4	0.2	–	–	–	–
25–29	–	0.1	0.9	0.5	11.4	8.7	–	–	0.1	–	–	–	0.1	–	0.6	–	0.2	0.1	0.9	0.2	0.1	–	–	0.1
30–34	0.2	0.2	1.7	1.0	13.6	9.9	0.4	–	0.2	–	–	–	0.1	0.1	0.6	0.5	0.3	0.2	1.7	0.6	0.1	0.1	0.5	0.1
35–39	0.8	0.5	3.6	1.8	14.8	8.7	1.2	0.3	0.6	–	1.7	–	0.2	0.1	0.6	0.5	0.4	0.2	2.0	0.8	0.4	0.2	0.9	0.4
40–44	2.2	1.1	7.4	4.0	12.5	8.1	1.2	0.6	1.2	–	1.7	–	0.5	0.2	1.2	0.5	0.8	0.5	3.1	1.3	0.6	0.3	1.4	0.9
45–49	5.6	2.5	11.2	7.1	9.1	7.0	2.7	1.4	2.2	0.5	1.7	–	1.0	0.4	2.4	2.1	1.6	1.0	5.0	2.3	1.4	0.9	3.3	1.6
50–54	11.5	5.4	14.8	10.0	6.8	5.2	3.9	2.3	3.8	0.8	3.4	–	2.1	1.1	4.1	3.6	2.8	1.8	7.3	4.4	3.6	2.0	5.2	3.4
55–59	17.9	9.0	13.7	12.0	5.7	5.2	6.6	2.8	5.1	1.6	5.2	3.6	4.3	2.8	6.5	4.7	4.3	3.2	10.3	6.8	5.7	4.0	9.5	5.9
60–64	17.3	11.4	14.0	12.1	4.5	5.2	8.1	5.4	8.0	2.4	8.6	7.1	7.0	5.3	11.8	6.7	8.2	5.8	11.7	8.9	10.5	7.0	13.7	7.9
65–69	15.1	13.4	11.8	13.3	3.4	6.4	11.2	7.3	12.8	7.3	13.8	7.1	13.7	11.2	16.0	12.4	12.9	11.7	14.7	11.0	17.1	12.7	17.5	12.4
70–74	12.7	15.3	9.9	13.6	4.5	7.6	19.0	16.1	17.1	15.1	19.0	10.7	21.7	19.8	16.0	16.1	20.7	18.8	15.8	14.8	22.6	20.2	20.9	17.9
75–79	11.7	18.6	6.3	13.2	6.8	11.0	19.4	24.3	20.9	29.3	19.0	17.9	26.0	27.8	20.1	23.3	24.1	25.4	14.7	21.4	23.5	27.4	18.5	24.1
80–84	4.8	22.6	4.2	11.1	3.4	12.8	26.4	39.5	27.9	43.0	25.9	53.6	23.3	31.2	20.1	29.5	23.5	31.3	12.5	27.1	14.2	25.2	8.5	25.3

* Except for cancer of corpus uteri, for which mortality rates are based on 1951–55 experience.

Table 2. Cancer of various sites. Mortality in each of five years from start of treatment or, if untreated, registration date, by site and clinical stage; 1945-48 registrations

Type of case	1st year			2nd year			3rd year			4th year			5th year			Five-year corrected survival rate	
	Number known to be alive at beginning of year	Number known to have died during year	Death rate per 100	Number known to be alive at beginning of year	Number known to have died during year	Death rate per 100	Number known to be alive at beginning of year	Number known to have died during year	Death rate per 100	Number known to be alive at beginning of year	Number known to have died during year	Death rate per 100	Number known to be alive at beginning of year	Number known to have died during year	Death rate per 100	Males	Females
CORPUS UTERI																	
EP_O - radically treated	811	93	11	712	77	11	634	47	7	585	38	6	540	32	6	-	68
EP_S, LP_O & LP_S - all cases	528	196	37	324	89	27	235	29	12	206	20	10	186	19	10	-	35
All registered cases	1,539	425	28	1,097	187	17	909	86	9	820	61	7	751	54	7	-	49
OVARY																	
EP_O - radically treated	324	62	19	257	26	10	231	21	9	207	22	11	184	8	4	-	57
EP_S, EP_O & LP_S - all cases	722	480	66	233	72	31	161	21	13	140	19	14	117	10	9	-	15
All registered cases	1,839	1,217	66	602	147	24	453	53	12	396	50	13	339	23	7	-	18
TESTIS																	
EP_O - radically treated	195	23	12	169	17	10	151	3	2	146	2	1	142	2	1	74	-
EP_S, LP_O & LP_S - all cases	89	42	47	47	10	21	37	3	8	34	2	6	30	0	0	36	-
All registered cases	352	122	35	226	29	13	196	6	3	188	6	3	178	2	1	52	-

PENIS																
EP_O - radically treated	186	18	10	166	19	11	146	18	12	126	11	9	112	7	6	71	-
EP_S, LP_O & LP_S - all cases	316	89	28	223	48	22	174	26	15	148	6	4	139	14	10	50	-
All registered cases	537	119	22	402	70	17	330	46	14	282	18	6	258	23	9	55	-
LIP																
EP_O - radically treated	1,453	96	7	1,347	110	8	1,235	79	6	1,141	62	5	1,064	63	6	88	90
EP_S, LP_O & LP_S - all cases	478	158	33	317	66	21	246	28	11	218	24	11	191	12	6	54	28
All registered cases	1,972	268	14	1,686	180	11	1,499	111	7	1,373	88	6	1,267	78	6	79	73
TONGUE																
EP_O - radically treated	776	177	23	598	153	26	443	55	12	387	41	11	341	32	9	47	57
EP_S, LP_O & LP_S - all cases	1,398	884	63	487	230	47	256	65	25	191	37	19	153	23	15	11	19
All registered cases	2,227	1,093	49	1,103	390	35	710	123	17	585	79	14	499	57	11	22	38
MOUTH, PHARYNX and TONSIL																
EP_O - radically treated	1,632	326	20	1,289	238	18	1,044	129	12	908	69	8	825	54	7	51	65
EP_S, LP_O & LP_S - all cases	4,223	2,572	61	1,577	684	43	890	212	24	675	101	15	570	75	13	14	17
All registered cases	6,115	3,059	50	2,949	952	32	1,985	354	18	1,620	176	11	1,425	131	9	23	32
OESOPHAGUS																
EP_O - radically treated	220	138	63	82	43	52	39	15	38	24	2	8	21	2	10	7	15
EP_S, LP_O & LP_S - all cases	1,686	1,521	90	129	88	68	41	19	46	22	2	9	20	6	30	1	1
All registered cases	2,191	1,923	88	230	144	63	86	37	43	49	4	8	44	8	18	1	3

Table 3. Cancer of Corpus Uteri. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
EARLY														
Registration rate	-	-	1	2	8	19	36	57	49	38	33	30	10	4
Comparative registration rate	-	-	0.3	0.7	2.8	6.6	12.5	19.9	17.1	13.2	11.5	10.5	3.5	1.4
LATE														
Registration rate	-	-	1	1	2	6	16	24	29	28	23	21	13	3
Comparative registration rate	-	-	0.6	0.6	1.2	3.6	9.6	14.4	17.4	16.8	13.8	12.6	7.8	1.8
METASTATIC														
Registration rate	-	-	-	-	1	3	5	8	8	9	7	6	1	-
Comparative registration rate	-	-	-	-	2.1	6.3	10.4	16.7	16.7	18.8	14.6	12.5	2.1	-

Table 4. Cancer of Corpus Uteri. Relationship of age to clinical stage; 1945–51 registrations

Age Group	Percentage distribution by clinical stage			Number registered (all stages)
	Early	Late	Metastatic	
0–	–	–	–	–
15–	80.0	20.0	–	5
25–	100.0	–	–	5
30–	46.7	40.0	13.3	15
35–	57.7	30.8	11.5	52
40–	70.5	16.7	12.9	132
45–	68.1	21.9	10.0	310
50–	63.3	28.1	8.6	569
55–	63.5	27.0	9.5	811
60–	57.6	33.4	9.0	701
65–	50.7	37.6	11.7	529
70–	52.2	35.9	11.9	345
75–	52.5	37.3	10.3	204
80–	43.2	54.5	2.3	44
85 and over	57.1	42.9	–	7
Not stated	60.0	40.0	–	20
All ages	**59.2**	**30.9**	**9.9**	**3,749**

Table 5. Cancer of Corpus Uteri. Relationship of duration of symptomatic history to clinical stage; 1945–51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage				Percentage distribution by stated duration of symptomatic history (all stages)
	Early	Late	Metastatic	All stages	
0–	60.5	28.8	10.7	100	11.4
2–	62.6	28.6	8.8	100	31.2
6–	58.0	31.4	10.6	100	22.0
12 and over	56.4	34.2	9.5	100	35.3
All durations (including "not stated")	**59.2**	**30.9**	**9.9**	**100**	–
Median duration of symptomatic history	7.1	8.1	7.6	7.5	–

Table 6. Cancer of Corpus Uteri. Number and percentage distribution by treatment in each clinical stage; 1945–51 registrations

Treatment	Early		Late		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	1,048	47.2	248	21.4	56	15.1
Radiotherapy	578	26.0	378	32.6	40	10.8
Surgery & Radiotherapy	515	23.2	176	15.2	48	13.0
PALLIATIVE						
Surgery	3	0.1	13	1.1	15	4.1
Radiotherapy	25	1.1	154	13.3	68	18.4
Surgery & Radiotherapy	4	0.2	6	0.5	8	2.2
OTHER	–	–	4	0.3	1	0.3
NONE	46	2.1	181	15.6	134	36.2
ALL CASES	**2,219**	**100**	**1,160**	**100**	**370**	**100**

(90058)

Table 7. Cancer of Corpus Uteri. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations.

Treatment	Clinical stage and age group											
	Early				Late				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0-	45-	60 and over		0-	45-	60 and over		0-	45-	60 and over
RADICAL												
Surgery	1,043	8	56	36	247	4	44	51	56	11	39	50
Radiotherapy	574	4	29	67	376	6	38	56	40	10	40	50
Surgery & Radiotherapy	512	7	59	34	176	4	57	39	48	6	54	40
PALLIATIVE	32	-	34	66	170	2	28	71	91	9	40	52
OTHER & NONE	46	-	46	54	183	1	27	72	135	3	42	55
ALL CASES	**2,207**	**6**	**49**	**44**	**1,152**	**4**	**39**	**57**	**370**	**7**	**42**	**51**

Table 8. **Cancer of Corpus Uteri.** Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations

Age Group	Radically treated cases						All cases		
	Early			Late					
	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected
0-	-	-	-	-	-	-	-	-	-
15-	-	-	-	1	*0*	*0*	1	*0*	*0*
25-	2	*50*	*50*	-	-	-	2	*50*	*50*
30-	2	*100*	*100*	4	*75*	*76*	8	*62*	*63*
35-	14	*71*	*72*	8	*25*	*25*	27	52	52
40-	31	68	69	9	*56*	*57*	53	57	58
45-	76	86	88	27	52	53	125	66	67
50-	129	75	78	59	58	60	230	57	60
55-	194	68	72	73	44	47	320	53	57
60-	165	58	64	76	36	39	295	43	47
65-	101	49	58	49	33	39	219	32	38
70-	70	30	41	26	31	42	148	22	29
75-	41	29	48	13	*23*	*38*	89	19	31
80-	5	*20*	*46*	3	*0*	*0*	14	*7*	*16*
85 and over	-	-	-	-	-	-	-	-	-
All stated ages	**830**	**61**	**67**	**348**	**41**	**46**	**1,531**	**44**	**49**

* Rates shown in italics are based on 20 or less cases at risk.

Table 9. Cancer of Corpus Uteri. Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of symptomatic history (months)	Early				Late				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0-	75	57	82	54	30	33	57	19	8	*0*	8	*0*	16	*0*	155	35
2-	240	55	249	53	90	41	124	33	30	13	17	*0*	47	9	420	42
6-	179	64	185	63	78	33	108	24	25	16	11	*0*	36	11	329	44
12 and over	273	65	280	64	136	47	180	37	36	22	20	*0*	56	14	516	49
Not stated	69	62	71	61	14	*50*	32	28	11	*9*	5	*0*	16	*6*	119	45
All durations	836	61	867	59	348	41	501	31	110	15	61	0	171	10	1,539	44

* Rates shown in italics are based on 20 or less cases at risk.

Table 10. Cancer of Ovary. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
EARLY														
Registration rate	1	2	3	5	10	14	19	15	13	11	10	5	1	3
Comparative registration rate	0.9	1.8	2.7	4.5	8.9	12.5	17.0	13.4	11.6	9.8	8.9	4.5	0.9	2.7
LATE														
Registration rate	1	1	2	7	16	21	31	29	33	26	21	17	10	3
Comparative registration rate	0.5	0.5	0.9	3.2	7.3	9.6	14.2	13.3	15.1	11.9	9.6	7.8	4.6	1.4
METASTATIC														
Registration rate	-	1	3	7	13	24	27	28	29	25	22	11	11	3
Comparative registration rate	-	0.5	1.5	3.4	6.4	11.8	13.2	13.7	14.2	12.3	10.8	5.4	5.4	1.5

Table 11. Cancer of Ovary. Relationship of age to clinical stage; 1945-51 registrations

Age Group	Percentage distribution by clinical stage			Number registered (all stages)
	Early	Late	Metastatic	
0-	33.3	55.6	11.1	9
15-	56.6	24.5	18.9	53
25-	42.6	27.9	29.5	61
30-	37.3	26.5	36.3	102
35-	26.5	39.1	34.3	230
40-	24.8	40.6	34.6	456
45-	23.7	36.1	40.1	653
50-	24.7	40.1	35.2	778
55-	21.3	40.2	38.5	657
60-	17.1	44.2	38.7	608
65-	17.5	41.7	40.8	441
70-	18.2	39.6	42.1	285
75-	14.5	51.3	34.2	117
80-	4.9	46.3	48.8	41
85 and over	33.3	33.3	33.3	9
Not stated	16.0	48.0	36.0	25
All ages	**22.5**	**40.0**	**37.5**	**4,525**

Table 12. **Cancer of Ovary.** Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage				Percentage distribution by stated duration of symptomatic history (all stages)
	Early	Late	Metastatic	All stages	
0-	31.5	38.4	30.1	100	6.7
1-	24.7	35.1	40.3	100	13.8
2-	19.1	40.0	40.8	100	14.7
3-	19.0	41.0	40.0	100	11.5
4-	20.2	42.8	37.1	100	8.8
5-	22.9	38.4	38.7	100	7.4
6-	21.0	39.2	39.9	100	13.7
9-	20.1	43.8	36.1	100	5.3
12-	22.7	40.6	36.7	100	9.1
18-	36.6	35.2	28.2	100	1.7
24 and over	27.5	42.6	29.9	100	7.2
All durations (including "not stated")	**22.5**	**40.0**	**37.5**	**100**	-
Median duration of symptomatic history	4.4	4.5	4.2	4.4	-

Table 13. Cancer of Ovary. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations

Treatment	Early		Late		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	523	51.4	372	20.6	148	8.7
Radiotherapy	23	2.3	116	6.4	42	2.5
Surgery & Radiotherapy	426	41.9	366	20.2	116	6.8
PALLIATIVE						
Surgery	12	1.2	141	7.8	214	12.6
Radiotherapy	8	0.8	201	11.1	170	10.0
Surgery & Radiotherapy	9	0.9	71	3.9	67	3.9
OTHER	1	0.1	6	0.3	8	0.5
NONE	15	1.5	536	29.6	934	55.0
ALL CASES	**1,017**	**100**	**1,809**	**100**	**1,699**	**100**

Table 14. Cancer of Ovary. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations

Treatment	Clinical stage and age group											
	Early				Late				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0-	45-	60 and over		0-	45-	60 and over		0-	45-	60 and over
RADICAL												
Surgery	521	26	46	28	370	22	43	35	147	20	54	26
Radiotherapy	22	32	45	23	116	31	46	23	42	29	52	19
Surgery & Radiotherapy	425	27	53	20	362	25	56	19	116	30	52	18
PALLIATIVE	29	31	38	31	410	18	49	34	449	22	48	31
OTHER & NONE	16	19	19	62	539	11	37	53	936	14	44	42
ALL CASES	**1,013**	**27**	**48**	**25**	**1,797**	**19**	**45**	**36**	**1,690**	**18**	**47**	**35**

Table 15. Cancer of Ovary. Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations

Age Group	Radically treated cases						All cases		
	Early			Late					
	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected
0-	2	*50*	*50*	2	*0*	*0*	6	*17*	*17*
15-	11	*55*	*55*	4	*25*	*25*	23	35	35
25-	30	63	64	7	*0*	*0*	74	28	29
35-	64	62	64	67	39	39	285	26	27
45-	102	43	45	99	27	28	571	15	15
55-	74	51	56	76	30	33	501	15	16
65-	44	55	66	33	15	19	299	11	14
75-	5	*60*	*100*	6	*17*	*27*	63	11	19
85 and over	1	*0*	*0*	-	-	-	2	*0*	*0*
All stated ages	**333**	**53**	**57**	**294**	**28**	**30**	**1,824**	**17**	**18**

* Rates shown in italics are based on 20 or less cases at risk.

Table 16. Cancer of Ovary. Number and five-year crude survival rates by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of Symptomatic history (months)	Early				Late				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0-	83	53	85	52	53	21	130	9	70	9	76	0	146	4	361	17
2-	102	52	113	49	120	24	276	13	129	8	180	1	309	4	698	15
6-	57	58	58	57	51	35	116	17	63	8	79	0	142	4	316	18
12 and over	62	56	63	56	51	39	124	20	59	7	54	2	113	4	300	22
Not stated	32	38	34	35	23	26	63	10	26	7	39	3	67	4	164	13
All durations	336	53	353	51	298	28	709	14	349	8	428	1	777	4	1,839	17

Table 17. Cancer of Testis. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
EP_O														
Registration rate	2	5	8	8	7	4	3	3	2	1	2	2	1	-
Comparative registration rate	4.2	10.4	16.7	16.7	14.6	8.3	6.2	6.2	4.2	2.1	4.2	4.2	2.1	-
EP_S, LP_O and LP_S														
Registration rate	1	3	3	3	3	3	2	1	2	1	1	4	1	2
Comparative registration rate	3.3	10.0	10.0	10.0	10.0	10.0	6.7	3.3	6.7	3.3	3.3	13.3	3.3	6.7
METASTATIC														
Registration rate	1	2	2	2	1	1	1	1	1	1	0	-	1	-
Comparative registration rate	7.1	14.3	14.3	14.3	7.1	7.1	7.1	7.1	7.1	7.1	0	-	7.1	-

Table 18. Cancer of Testis. Relationship of age to clinical stage; 1945-51 registrations

Age Group	Percentage distribution by clinical stage					Number registered (all stages)
	EP_0	EP_S	LP_0	LP_S	Met.	
0-	66.7	-	33.3	-	-	9
15-	52.5	6.6	6.6	6.6	27.9	61
25-	53.0	2.6	13.0	9.6	21.7	115
30-	63.3	3.9	9.4	8.6	14.8	128
35-	61.5	2.6	10.3	10.9	14.7	156
40-	62.2	3.1	13.4	9.4	11.8	127
45-	56.4	3.8	16.7	12.8	10.3	78
50-	53.7	7.4	11.1	7.4	20.4	54
55-	68.6	-	8.6	8.6	14.3	35
60-	44.8	6.9	13.8	20.7	13.8	29
65-	41.2	5.9	5.9	23.5	23.5	17
70-	58.8	-	29.4	5.9	5.9	17
75-	35.7	7.1	42.9	14.3	-	14
80-	33.3	-	-	33.3	33.3	3
85 and over	-	-	100	-	-	1
Not stated	66.7	-	-	-	33.3	3
All ages	**57.9**	**3.7**	**12.5**	**10.2**	**15.8**	**847**

Table 19. Cancer of Testis. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage				Percentage distribution by stated duration of symptomatic history (all stages)
	EP_0	EP_S, LP_0 and LP_S	Metastatic	All stages	
0-	61.4	19.3	19.3	100	14.2
2-	62.1	25.4	12.5	100	40.7
6-	58.0	26.5	15.4	100	20.2
12 and over	51.5	30.0	18.5	100	24.9
All durations (including "not stated")	**57.9**	**26.3**	**15.8**	**100**	-
Median duration of symptomatic history	4.9	5.9	6.0	5.2	-

Table 20. Cancer of Testis. Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations

Treatment	EP_0		EP_S, LP_0 and LP_S		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	81	16.5	26	11.7	7	5.2
Radiotherapy	8	1.6	12	5.4	11	8.2
Surgery & Radiotherapy	393	80.2	137	61.4	34	25.4
PALLIATIVE						
Surgery	1	0.2	2	0.9	7	5.2
Radiotherapy	3	0.6	20	9.0	23	17.2
Surgery & Radiotherapy	1	0.2	14	6.3	22	16.4
OTHER	-	-	1	0.4	1	0.7
NONE	3	0.6	11	4.9	29	21.6
ALL CASES	**490**	**100**	**223**	**100**	**134**	**100**

Table 21. Cancer of Testis. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945–51 registrations

Treatment	Clinical stage and age group											
	EP_O				EP_S, LP_O and LP_S				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over
RADICAL												
Surgery	80	59	24	18	26	62	12	27	7	100	–	–
Radiotherapy	8	88	–	12	12	58	25	17	11	100	–	–
Surgery & Radiotherapy	392	76	19	5	137	69	20	12	34	76	18	6
PALLIATIVE	5	60	20	20	36	50	33	17	51	78	14	8
OTHER and NONE	3	67	33	–	12	58	8	33	30	50	37	13
ALL CASES	**488**	**73**	**20**	**7**	**223**	**64**	**21**	**16**	**133**	**74**	**18**	**8**

Table 22. Cancer of Testis. Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945–48 registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate	
		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected
0–	3	*33*	*34*	–	–	–	1	*0*	*0*	–	–	–	4	*25*	*25*
15–	13	*62*	*62*	2	*50*	*50*	–	–	–	1	*0*	*0*	23	39	39
25–	22	64	64	3	*0*	*0*	7	*29*	*29*	2	*50*	*50*	50	40	40
30–	33	70	70	2	*50*	*50*	3	*33*	*34*	6	*33*	*34*	55	51	51
35–	37	78	80	2	*100*	*100*	2	*100*	*100*	3	*0*	*0*	58	62	63
40–	34	76	78	2	*50*	*52*	6	*33*	*34*	2	*0*	*0*	54	56	57
45–	20	*80*	*84*	1	*0*	*0*	7	*57*	*60*	2	*50*	*52*	38	58	60
50–	10	*80*	*86*	2	*50*	*54*	–	–	–	–	–	–	22	45	49
55–	13	*62*	*69*	–	–	–	1	*100*	*100*	2	*0*	*0*	19	*47*	*53*
60–	3	*100*	*100*	1	*0*	*0*	1	*100*	*100*	2	*50*	*60*	11	*45*	*54*
65–	2	*50*	*66*	–	–	–	1	*100*	*100*	2	*50*	*66*	8	*38*	*49*
70–	2	*50*	*76*	–	–	–	1	*0*	*0*	–	–	–	5	*20*	*30*
75–	1	*0*	*0*	–	–	–	–	–	–	–	–	–	2	*0*	*0*
80–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
85 and over	–	–	–	–	–	–	1	*0*	*0*	–	–	–	1	*0*	*0*
All stated ages	193	72	74	15	40	41	31	45	48	22	27	30	350	50	52

* Rates shown in italics are based on 20 or less cases at risk.

Table 23. Cancer of Testis. Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945–48 registrations

Duration of symptomatic history (months)	EP_0				EP_S, LP_0 and LP_S				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0–	26	73	26	73	4	*50*	8	*25*	7	*14*	5	*0*	12	*8*	46	48
2–	82	76	83	76	23	35	29	31	14	*7*	7	*0*	21	5	133	55
6–	39	67	39	67	14	*29*	19	*32*	5	*0*	1	*0*	6	*0*	64	50
12 and over	40	68	41	68	20	*50*	25	44	17	*6*	3	*0*	20	*5*	86	47
Not stated	8	*62*	8	*62*	7	*29*	8	*25*	4	*25*	3	*0*	7	*14*	23	35
All durations	**195**	**71**	**197**	**72**	**68**	**38**	**89**	**34**	**47**	**9**	**19**	**0**	**66**	**6**	**352**	**50**

* Rates shown in italics are based on 20 or less cases at risk.

Table 24. Cancer of Penis. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945–51 registrations

Clinical stage	Age Group													
	15–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85 and over
EP_0														
Registration rate	–	–	0	1	2	3	4	8	8	14	21	19	24	16
Comparative registration rate	–	–	0	0.8	1.7	2.5	3.3	6.7	6.7	11.7	17.5	15.8	20.0	13.3
EP_S, LP_0 and LP_S														
Registration rate	–	0	1	1	2	4	5	8	12	14	27	30	43	32
Comparative registration rate	–	0	0.6	0.6	1.1	2.2	2.8	4.5	6.7	7.8	15.1	16.8	24.0	17.9
METASTATIC														
Registration rate	–	–	–	–	–	–	0	1	0	1	1	1	–	2
Comparative registration rate	–	–	–	–	–	–	0	16.7	0	16.7	16.7	16.7	–	33.3

Table 25. Cancer of Penis. Relationship of age to clinical stage; 1945-51 registrations

Age Group	Percentage distribution by clinical stage					Number registered (all stages)
	EP_0	EP_S	LP_0	LP_S	Met.	
0-	-	-	-	-	-	-
15-	-	-	-	-	-	-
25-	-	-	-	100.0	-	1
30-	21.4	35.7	-	42.9	-	14
35-	48.5	12.1	9.1	30.3	-	33
40-	47.5	20.0	7.5	25.0	-	40
45-	42.0	21.7	8.7	27.5	-	69
50-	46.9	18.5	8.6	23.5	2.5	81
55-	45.6	12.8	8.0	30.4	3.2	125
60-	39.7	16.9	11.8	29.4	2.2	136
65-	49.4	15.0	10.6	23.1	1.9	160
70-	42.8	12.4	12.9	29.9	2.0	201
75-	37.9	11.3	12.9	36.3	1.6	124
80-	36.0	16.0	21.3	26.7	-	75
85 and over	31.8	4.5	36.4	22.7	4.5	22
Not stated	60.0	20.0	-	20.0	-	5
All ages	**42.8**	**15.0**	**11.8**	**28.6**	**1.7**	**1,086**

Table 26. Cancer of Penis. Relationship of duration of symptomatic history to clinical stage; 1945–51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage				Percentage distribution by stated duration of symptomatic history (all stages)
	EP_0	EP_S, LP_0 and LP_S	Metastatic	All stages	
0–	47.1	50.0	2.9	100	10.3
2–	41.0	58.0	1.0	100	39.7
6–	45.6	51.2	3.3	100	21.4
12 and over	41.5	57.1	1.4	100	28.7
All durations (including "Not stated")	**42.8**	**55.4**	**1.7**	**100**	–
Median duration of symptomatic history	6.1	5.9	7.2	6.0	–

Table 27. Cancer of Penis. Number and percentage distribution by treatment in each clinical stage; 1945–51 registrations

Treatment	EP_0		EP_S, LP_0 and LP_S		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	201	43.2	205	34.1	5	26.3
Radiotherapy	124	26.7	96	15.9	1	5.3
Surgery and Radiotherapy	93	20.0	138	22.9	1	5.3
PALLIATIVE						
Surgery	4	0.9	30	5.0	–	–
Radiotherapy	5	1.1	30	5.0	5	26.3
Surgery and Radiotherapy	–	–	20	3.3	1	5.3
OTHER	8	1.7	6	1.0	–	–
NONE	30	6.5	77	12.8	6	31.6
ALL CASES	**465**	**100**	**602**	**100**	**19**	**100**

Table 28. Cancer of Penis. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations

Treatment	Clinical stage and age group											
	EP_0				EP_s, LP_0 and LP_s				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0-	45-	60 and over		0-	45-	60 and over		0-	45-	60 and over
RADICAL												
Surgery	200	6	24	70	204	6	32	61	5	-	60	40
Radiotherapy	123	7	28	66	96	12	19	69	1	-	-	100
Surgery & Radiotherapy	92	16	39	45	138	10	30	59	1	-	-	100
PALLIATIVE	9	-	-	100	80	8	15	78	6	-	17	83
OTHER & NONE	38	8	18	74	82	6	9	85	6	-	33	67
ALL CASES	**462**	**8**	**27**	**65**	**600**	**8**	**24**	**68**	**19**	**-**	**32**	**68**

Table 29. Cancer of Penis. Number and five-year survival rates*, crude and corrected, of radically treated cases, by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected
0-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25-	3	*33*	*34*	2	*100*	*100*	-	-	-	3	*0*	*0*	10	*40*	*40*
35-	12	*58*	*60*	7	*43*	*44*	1	*0*	*0*	10	*40*	*41*	36	42	43
45-	31	77	82	17	*47*	*49*	8	*62*	*66*	16	*50*	*53*	82	57	61
55-	55	64	73	21	62	71	10	*70*	*81*	41	46	53	148	51	59
65-	56	48	68	19	*53*	*73*	17	*53*	*74*	44	43	62	170	40	56
75-	25	36	75	9	*33*	*73*	6	*17*	*32*	15	*33*	*63*	77	26	53
85 and over	1	*0*	*0*	-	-	-	-	-	-	-	-	-	7	*0*	*0*
All stated ages	**183**	**56**	**71**	**75**	**52**	**65**	**42**	**52**	**67**	**129**	**43**	**55**	**530**	**43**	**55**

* Rates shown in italics are based on 20 or less cases at risk.

Table 30. Cancer of Penis. Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of symptomatic history (months)	EP_0				EP_s				LP_0				LP_s				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0-	20	*45*	22	41	4	*50*	5	*40*	3	*67*	5	*40*	12	*33*	17	*29*	1	*0*	-	-	1	*0*	50	36
2-	60	52	69	49	33	39	35	40	19	*37*	23	30	51	55	68	46	-	-	2	*0*	2	*0*	197	44
6-	45	62	47	62	17	*59*	17	*59*	6	*50*	7	*43*	23	30	30	27	3	*0*	2	*0*	5	*0*	106	47
12 and over	47	55	55	49	20	*65*	20	*65*	11	*73*	19	*42*	32	34	45	24	5	*0*	-	-	5	*0*	144	41
Not stated	14	*71*	14	*71*	2	*100*	2	*100*	3	*67*	7	*29*	11	*45*	16	*31*	-	-	1	*0*	1	*0*	40	48
All durations	186	56	207	53	76	53	79	52	42	52	61	36	129	43	176	34	9	*0*	5	*0*	14	*0*	537	43

* Rates shown in italics are based on 20 or less cases at risk.

Table 31. Cancer of Lip. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
	MALES													
EP_O														
Registration rate	0	1	2	4	10	18	28	38	59	91	112	132	171	182
Comparative registration rate	-	0.1	0.2	0.5	1.2	2.1	3.3	4.5	7.0	10.7	13.2	15.6	20.2	21.5
EP_S, LP_O and LP_S														
Registration rate	-	0	0	1	2	2	6	8	13	24	41	56	80	129
Comparative registration rate	-	-	-	0.3	0.6	0.6	1.7	2.2	3.6	6.6	11.3	15.5	22.1	35.6
METASTATIC														
Registration rate	-	-	-	-	-	0	-	-	0	1	1	0	1	2
Comparative registration rate	-	-	-	-	-	-	-	-	-	20.0	20.0	-	20.0	40.0
	FEMALES													
EP_O														
Registration rate	0	0	0	1	1	1	2	3	3	6	10	9	9	8
Comparative registration rate	-	-	-	1.9	1.9	1.9	3.8	5.7	5.7	11.3	18.9	17.0	17.0	15.1
EP_S, LP_O and LP_S														
Registration rate	-	-	-	-	0	0	0	0	2	1	2	2	4	6
Comparative registration rate	-	-	-	-	-	-	-	-	11.8	5.9	11.8	11.8	23.5	35.3
METASTATIC														
Registration rate	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Comparative registration rate	-	-	-	-	-	-	-	-	-	-	-	-	100	-

Table 32. Cancer of Lip **PERSONS**

Relationship of age to clinical stage; 1945-51 registrations

Age Group	Percentage distribution by clinical stage					Number registered (all stages)
	EP_0	EP_S	LP_0	LP_S	Met	
0-	-	-	-	-	-	-
15-	100	-	-	-	-	5
25-	91.5	4.3	2.1	2.1	-	47
35-	82.5	10.4	3.3	3.8	-	211
45-	84.1	9.3	1.9	4.5	0.2	529
55-	81.6	8.1	4.4	5.6	0.2	887
65-	76.5	7.4	5.5	10.0	0.6	1,381
75-	69.5	6.5	10.5	12.9	0.5	811
85 and over	58.0	12.0	15.3	14.0	0.7	150
Not stated	79.3	3.4	6.9	10.3	-	29
All ages	**77.1**	**7.9**	**6.0**	**8.6**	**0.4**	**4,050**

Table 33. Cancer of Lip. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage (Persons)				EP_O Percentage of all stages		Percentage distribution by stated duration of symptomatic history (all stages)		
	EP_O	EP_S, LP_O and LP_S	Met.	All stages	Males	Females	Males	Females	Persons
0-	84.5	15.2	0.3	100	83.8	91.2	8.3	11.1	8.6
2-	80.1	19.5	0.4	100	80.1	79.7	39.6	38.7	39.5
6-	75.7	23.9	0.4	100	75.4	80.0	20.2	18.0	20.0
12 and over	72.8	26.7	0.4	100	72.7	74.5	31.9	32.1	31.9
All durations (including "not stated")	**77.1**	**22.5**	**0.4**	**100**	**76.8**	**80.1**	-	-	-
Median duration of symptomatic history	6.0	7.9	9.0	6.4	6.0	5.7	6.4	6.1	6.4

Table 34. Cancer of Lip **PERSONS**

Number and percentage distribution by treatment in each clinical stage; 1945-51 registrations

Treatment	EP_0		EP_S, LP_0 and LP_S		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	217	7.0	31	3.4	1	6.2
Radiotherapy	2,601	83.3	537	58.9	7	43.8
Surgery & Radiotherapy	236	7.6	152	16.7	3	18.8
PALLIATIVE						
Surgery	1	0.0	-	-	-	-
Radiotherapy	18	0.6	138	15.1	3	18.8
Surgery & Radiotherapy	1	0.0	11	1.2	-	-
OTHER	2	0.1	-	-	-	-
NONE	46	1.5	43	4.7	2	12.5
ALL CASES	**3,122**	**100**	**912**	**100**	**16**	**100**

Table 35. Cancer of Lip

PERSONS

Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945-51 registrations

Treatment	Clinical stage and age group											
	EP_0				EP_S, LP_0 and LP_S				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0-	45-	60 and over		0-	45-	60 and over		0-	45-	60 and over
RADICAL												
Surgery	216	13	29	58	31	10	35	55	1	-	-	100
Radiotherapy	2,583	6	24	70	533	4	17	79	7	-	-	100
Surgery & Radiotherapy	233	10	30	60	151	8	24	68	3	-	33	67
PALLIATIVE	20	5	-	95	149	1	6	93	3	-	-	100
OTHER & NONE	47	13	23	64	42	2	2	95	2	-	-	100
ALL CASES	**3,099**	**7**	**24**	**68**	**906**	**5**	**16**	**79**	**16**	-	**6**	**94**

Table 36. Cancer of Lip PERSONS

Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945-48 registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected	Number	Survival rate Crude	Corrected
0-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15-	2	*100*	*100*	-	-	-	-	-	-	-	-	-	2	*100*	*100*
25-	6	*67*	*67*	-	-	-	1	*100*	*100*	-	-	-	8	*62*	*63*
30-	11	*73*	*74*	1	*100*	*100*	-	-	-	-	-	-	14	*64*	*65*
35-	21	76	77	7	*57*	*58*	3	*67*	*68*	1	*0*	*0*	32	69	70
40-	54	76	78	6	*67*	*68*	1	*100*	*100*	2	*50*	*52*	65	75	77
45-	95	89	93	7	*86*	*89*	1	*0*	*0*	5	*80*	*84*	111	86	90
50-	118	84	90	13	*85*	*91*	3	*67*	*72*	7	*43*	*46*	142	81	87
55-	154	86	96	18	*72*	*81*	6	*50*	*55*	9	*33*	*37*	196	80	89
60-	205	83	99	16	*56*	*66*	17	*41*	*49*	9	*33*	*40*	262	73	87
65-	250	64	83	22	32	42	13	*54*	*70*	22	36	48	330	56	73
70-	248	63	94	24	50	74	24	50	76	36	31	46	358	54	81
75-	167	44	82	19	*47*	*90*	18	*44*	*84*	20	*35*	*67*	245	40	75
80-	74	32	87	8	*25*	*68*	6	*17*	*46*	9	*0*	*0*	129	21	56
85 and over	38	8	34	10	*20*	*86*	7	*14*	*61*	1	*0*	*0*	63	11	48
All stated ages	1,443	67	88	151	53	73	100	45	67	121	33	46	1,957	59	78

* Rates shown in italics are based on 20 or less cases at risk

Table 37. Cancer of Lip.
Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

PERSONS

Duration of symptomatic history (months)	EP_0				EP_S				LP_0				LP_S				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0-	138	67	143	66	11	*45*	11	*45*	5	*80*	6	*67*	7	*14*	11	*9*	-	-	-	-	-	-	171	61
2-	572	64	584	63	62	45	67	43	23	52	25	48	38	42	61	26	3	*33*	1	*0*	4	*25*	741	57
6-	283	71	290	70	31	52	35	49	21	33	24	29	26	23	36	17	2	*0*	-	-	2	*0*	387	60
12- and over	389	71	393	71	39	72	46	67	49	43	62	39	48	33	70	24	3	*0*	1	*0*	4	*0*	575	61
Not stated	71	63	73	62	8	*38*	8	*38*	3	*67*	4	*50*	5	*40*	12	*17*	1	*0*	-	-	1	*0*	98	53
All durations	1,453	67	1,483	67	151	53	167	51	101	46	121	40	124	33	190	22	9	*11*	2	*0*	11	*9*	1,972	59

* Rates shown in italics are based on 20 or less cases at risk

Table 38. Cancer of Tongue. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945–51 registrations

Clinical stage	Age Group													
	15–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80–	85 and over
	MALES													
EP_O														
Registration rate	–	–	–	1	2	4	8	12	23	36	53	62	49	46
Comparative registration rate	–	–	–	0.3	0.7	1.4	2.7	4.1	7.8	12.2	17.9	20.9	16.6	15.5
EP_S, LP_O, LP_S and Metastatic														
Registration rate	–	–	1	1	2	4	10	24	36	78	129	155	147	85
Comparative registration rate	–	–	0.1	0.1	0.3	0.6	1.5	3.6	5.4	11.6	19.2	23.1	21.9	12.6
All cases														
Registration rate	–	1	1	2	4	8	18	36	59	115	182	218	196	131
Comparative registration rate	–	0.1	0.1	0.2	0.4	0.8	1.9	3.7	6.1	11.8	18.7	22.4	20.2	13.5
	FEMALES													
EP_O														
Registration rate	–	1	–	1	1	3	4	6	12	14	14	18	14	15
Comparative registration rate	–	1.0	–	1.0	1.0	2.9	3.9	5.8	11.7	13.6	13.6	17.5	13.6	14.6
EP_S, LP_O, LP_S and Metastatic														
Registration rate	–	–	1	1	1	2	3	6	7	13	13	17	20	12
Comparative registration rate	–	–	1.0	1.0	1.0	2.1	3.1	6.2	7.3	13.5	13.5	17.7	20.8	12.5
All cases														
Registration rate	–	1	1	1	2	4	7	11	20	27	27	34	34	26
Comparative registration rate	–	0.5	0.5	0.5	1.0	2.1	3.6	5.6	10.3	13.8	13.8	17.4	17.4	13.3

Table 39. Cancer of Tongue. Relationship of age to clinical stage; 1945–51 registrations

MALES						Age Group	FEMALES					
Percentage distribution by clinical stage					Number registered (all stages)		Percentage distribution by clinical stage					Number registered (all stages)
EP_0	EP_S	LP_0	LP_S	Met.			EP_0	EP_S	LP_0	LP_S	Met.	
–	–	–	–	–	–	0–	–	–	–	–	–	–
66.7	–	–	33.3	–	3	15–	50.0	50.0	–	–	–	4
44.4	27.8	5.6	22.2	–	18	25–	45.5	9.1	–	45.5	–	22
46.2	10.8	9.2	33.8	–	65	35–	50.0	11.4	18.2	20.4	–	44
45.9	13.5	10.9	28.4	1.3	229	45–	59.6	7.0	12.3	20.2	0.9	114
36.1	13.8	10.9	37.3	1.8	659	55–	58.1	9.1	10.6	21.9	0.4	265
30.4	12.4	16.7	39.2	1.3	1,380	65–	51.6	9.5	13.9	24.3	0.6	337
27.6	7.1	20.4	44.1	0.8	758	75–	48.1	9.7	12.4	29.7	–	185
35.1	7.0	24.6	31.6	1.8	57	85 and over	56.0	12.0	12.0	20.0	–	25
25.0	6.2	12.5	56.2	–	16	Not stated	57.1	14.3	14.3	14.3	–	7
32.5	**11.4**	**15.9**	**38.9**	**1.3**	**3,185**	**All ages**	**53.5**	**9.5**	**12.4**	**24.2**	**0.4**	**1,003**

Table 40. Cancer of Tongue. Relationship of duration of symptomatic history to clinical stage; 1945–51 registrations

MALES							Duration of symptomatic history (months)	FEMALES						
Percentage distribution by clinical stage						Percentage distribution by stated duration of symptomatic history (all stages)		Percentage distribution by clinical stage						Percentage distribution by stated duration of symptomatic history (all stages)
EP_O	EP_S	LP_O	LP_S	Met.	All stages			EP_O	EP_S	LP_O	LP_S	Met.	All stages	
39.9	12.9	12.2	34.1	0.9	100	14.9	0–	61.5	11.5	9.4	17.7	–	100	10.3
32.2	12.2	15.6	38.9	1.1	100	52.7	2–	54.4	9.8	10.5	25.1	0.2	100	49.1
30.1	9.2	15.8	43.3	1.6	100	16.5	6–	51.4	6.9	14.3	26.9	0.6	100	18.8
31.8	10.0	18.7	38.0	1.5	100	15.9	12 and over	52.9	8.8	15.2	22.5	0.5	100	21.9
32.5	**11.4**	**15.9**	**38.9**	**1.3**	**100**	–	**All durations (including "not stated")**	**53.5**	**9.5**	**12.4**	**24.2**	**0.4**	**100**	–
3.7	3.7	4.2	4.0	4.8	3.9	–	Median duration of symptomatic history	4.5	4.1	6.0	4.8	12.0	4.6	–

Table 41. Cancer of Tongue. Number and percentage distribution by treatment in each clinical stage; 1945–51 registrations

MALES								Treatment	FEMALES							
EP_0		EP_S		LP_0, LP_S and Metastatic		All cases			EP_0		EP_S		LP_0, LP_S and Metastatic		All cases	
Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution		Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
								RADICAL								
82	7.9	14	3.8	44	2.5	140	4.4	Surgery	45	8.4	4	4.2	8	2.2	57	5.7
706	68.1	181	49.7	639	35.8	1,526	47.9	Radiotherapy	358	66.7	43	45.3	144	38.8	545	54.3
198	19.1	118	32.4	121	6.8	437	13.7	Surgery & Radiotherapy	110	20.5	37	38.9	38	10.2	185	18.4
								PALLIATIVE								
–	–	2	0.5	6	0.3	8	0.3	Surgery	–	–	–	–	1	0.3	1	0.1
20	1.9	41	11.3	639	35.8	700	22.0	Radiotherapy	7	1.3	5	5.3	122	32.9	134	13.4
2	0.2	1	0.3	20	1.1	23	0.7	Surgery & Radiotherapy	2	0.4	–	–	–	–	2	0.2
–	–	–	–	2	0.1	2	0.1	OTHER	1	0.2	–	–	–	–	1	0.1
28	2.7	7	1.9	314	17.6	349	11.0	NONE	14	2.6	6	6.3	58	15.6	78	7.8
1,036	100	364	100	1,785	100	3,185	100	ALL CASES	537	100	95	100	371	100	1,003	100

Table 42. Cancer of Tongue. PERSONS

Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945–51 registrations

Treatment	Clinical stage and age group																	
	EP_0				EP_s				LP_0				LP_s				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over
RADICAL																				
Surgery	125	7	22	70	18	–	28	72	16	–	19	81	34	6	32	62	2	–	–	100
Radiotherapy	1,060	4	18	78	223	3	18	79	316	3	16	81	455	4	15	81	6	–	50	50
Surgery & Radiotherapy	306	8	29	63	155	9	28	63	60	3	22	75	94	11	26	64	4	–	50	50
PALLIATIVE	31	–	6	94	48	–	6	94	156	–	8	92	609	2	15	83	18	–	28	72
OTHER and NONE	43	–	9	91	13	–	15	85	78	3	6	91	281	1	8	90	14	–	–	100
ALL CASES	**1,565**	**5**	**20**	**75**	**457**	**5**	**20**	**75**	**626**	**2**	**13**	**84**	**1,473**	**3**	**15**	**82**	**44**	**–**	**23**	**77**

Table 43. Cancer of Tongue. Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945–48 registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate	
		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected
							MALES								
0–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
15–	1	*100*	*100*	–	–	–	–	–	–	1	*0*	*0*	2	*50*	*50*
25–	–	–	–	1	*0*	*0*	–	–	–	–	–	–	1	*0*	*0*
30–	3	*100*	*100*	2	*50*	*50*	1	*0*	*0*	1	*100*	*100*	7	*71*	*72*
35–	–	–	–	2	*0*	*0*	1	*0*	*0*	8	*0*	*0*	11	*0*	*0*
40–	13	*62*	*63*	2	*0*	*0*	–	–	–	5	*0*	*0*	23	35	36
45–	21	52	55	8	*0*	*0*	6	*50*	*52*	4	*25*	*26*	43	35	39
50–	35	54	58	10	*20*	*22*	4	*0*	*0*	15	*27*	*29*	84	32	34
55–	44	43	48	20	*20*	*22*	9	*22*	*25*	34	21	23	142	23	25
60–	88	43	52	26	*27*	*32*	19	*16*	*19*	35	17	20	228	25	29
65–	114	39	51	45	22	29	31	16	21	72	3	4	365	17	23
70–	111	24	*37*	38	16	24	44	14	21	74	12	18	434	12	18
75–	70	23	43	11	*18*	*35*	26	4	7	25	4	8	264	8	15
80–	24	12	34	6	*0*	*0*	10	*10*	*27*	12	*0*	*0*	109	5	13
85 and over	8	*12*	*54*	2	*0*	*0*	2	*50*	*100*	4	*0*	*0*	26	8	33
All stated ages	**532**	**36**	**47**	**173**	**18**	**24**	**153**	**14**	**22**	**290**	**11**	**14**	**1,739**	**16**	**22**

FEMALES

0–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
15–	1	*0*	*0*	1	*100*	*100*	–	–	–	–	–	–	2	*50*	*50*
25–	2	*50*	*50*	1	*0*	*0*	–	–	–	–	–	–	3	*33*	*34*
30–	1	*100*	*100*	–	–	–	–	–	–	2	*0*	*0*	3	*33*	*34*
35–	2	*50*	*50*	–	–	–	1	*100*	*100*	2	*0*	*0*	6	*33*	*34*
40–	4	*75*	*76*	2	*0*	*0*	2	*50*	*51*	3	*33*	*34*	11	*45*	*46*
45–	17	*53*	*54*	2	*0*	*0*	1	*0*	*0*	4	*50*	*52*	28	39	40
50–	17	*65*	*67*	1	*0*	*0*	7	*29*	*30*	3	*0*	*0*	38	39	41
55–	24	50	53	4	*50*	*53*	5	*20*	*21*	4	*25*	*27*	44	38	39
60–	39	59	65	8	*25*	*28*	4	*50*	*56*	9	*22*	*25*	70	41	46
65–	52	44	53	15	*47*	*56*	6	*0*	*0*	11	*0*	*0*	108	29	34
70–	41	41	56	4	*50*	*68*	5	*40*	*54*	6	*17*	*22*	71	31	42
75–	25	*36*	59	5	*0*	*0*	4	*25*	*41*	5	*0*	*0*	52	21	35
80–	11	*27*	*62*	2	*50*	*100*	–	–	–	–	–	–	30	13	30
85 and over	5	*0*	*0*	1	*0*	*0*	–	–	–	–	–	–	11	*0*	*0*
All stated ages	241	47	57	46	33	41	35	29	34	49	14	16	477	31	38

* Rates shown in italics are based on 20 or less cases at risk.

Table 44. Cancer of Tongue. Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of symptomatic (months)	EP_0				EP_S				LP_0				LP_S				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
MALES																								
0-	85	33	87	32	26	15	34	15	17	29	32	19	29	7	80	4	3	0	-	-	3	0	236	18
2-	283	33	291	32	87	17	106	15	79	14	126	9	159	11	366	5	7	0	3	0	10	0	899	16
6-	74	28	76	28	21	38	25	32	26	8	45	4	45	7	108	5	2	0	2	0	4	0	258	14
12 and over	74	53	79	51	30	17	30	17	25	12	36	11	50	14	121	7	-	-	3	0	3	0	269	21
Not stated	19	47	22	41	9	0	11	0	7	14	15	7	10	10	38	3	-	-	1	0	1	0	87	13
All durations	535	36	555	35	173	18	206	17	154	14	254	9	293	11	713	5	12	0	9	0	21	0	1,749	16

FEMALES

0-	29	59	32	56	4	*0*	4	*0*	1	*0*	4	*0*	2	*0*	10	*0*	-	-	-	-	-	-	50	36
2-	117	47	120	46	28	43	29	41	16	*31*	19	*26*	24	8	51	4	-	-	-	-	-	-	219	34
6-	43	37	43	37	4	*25*	7	*14*	6	*17*	11	*9*	11	*18*	22	9	1	*0*	-	-	1	*0*	84	24
12 and over	40	50	42	48	7	*14*	8	*12*	11	*36*	15	*33*	11	*18*	30	13	1	*0*	-	-	1	*0*	96	31
Not stated	12	*42*	14	*36*	3	*33*	4	*25*	1	*0*	4	*0*	2	*50*	7	*14*	-	-	-	-	-	-	29	24
All durations	241	47	251	45	46	33	52	29	35	29	53	21	50	14	120	8	2	*0*	-	-	2	*0*	478	31

* Rates shown in italics are based on 20 or less cases at risk.

Table 45. Cancer of Mouth, Pharynx and Tonsil. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
							MALES							
EP_O														
Registration rate	1	2	3	5	6	12	18	24	43	68	104	113	108	74
Comparative registration rate	0.2	0.3	0.5	0.9	1.0	2.1	3.1	4.1	7.4	11.7	17.9	19.5	18.6	12.7
EP_S														
Registration rate	0	0	1	1	1	4	7	10	17	29	39	36	37	18
Comparative registration rate	-	-	0.5	0.5	0.5	2.0	3.5	5.0	8.5	14.5	19.5	18.0	18.5	9.0
LP_O														
Registration rate	0	0	1	1	3	5	9	15	29	52	90	123	125	115
Comparative registration rate	-	-	0.2	0.2	0.5	0.9	1.6	2.6	5.1	9.2	15.8	21.7	22.0	20.2
LP_S														
Registration rate	1	1	2	2	6	12	22	37	77	117	191	221	208	141
Comparative registration rate	0.1	0.1	0.2	0.2	0.6	1.2	2.1	3.6	7.4	11.3	18.4	21.3	20.0	13.6
METASTATIC														
Registration rate	0	0	0	0	1	1	2	3	4	4	9	8	11	7
Comparative registration rate	-	-	-	-	2.0	2.0	4.0	6.0	8.0	8.0	18.0	16.0	22.0	14.0

FEMALES

EP_0														
Registration rate	1	3	5	5	8	10	12	20	19	24	25	21	17	14
Comparative registration rate	0.5	1.6	2.7	2.7	4.3	5.4	6.5	10.9	10.3	13.0	13.6	11.4	9.2	7.6
EP_S														
Registration rate	-	-	-	-	1	2	3	3	4	6	5	4	4	4
Comparative registration rate	-	-	-	-	2.8	5.6	8.3	8.3	11.1	16.7	13.9	11.1	11.1	11.1
LP_0														
Registration rate	-	1	2	2	4	7	10	16	18	25	25	27	25	22
Comparative registration rate	-	0.5	1.1	1.1	2.2	3.8	5.4	8.7	9.8	13.6	13.6	14.7	13.6	12.0
LP_S														
Registration rate	-	-	1	3	3	9	14	16	22	22	27	27	22	15
Comparative registration rate	-	-	0.6	1.7	1.7	5.0	7.7	8.8	12.2	12.2	14.9	4.9	12.2	8.3
METASTATIC														
Registration rate	-	-	-	-	1	-	1	1	2	3	3	2	1	1
Comparative registration rate	-	-	-	-	6.7	-	6.7	6.7	13.3	20.0	20.0	13.3	6.7	6.7

Table 46. Cancer of Mouth, Pharynx and Tonsil. Relationship of age to clinical stage; 1945-51 registrations

MALES						Age Group	FEMALES					
Percentage distribution by clinical stage					Number registered (all stages)		Percentage distribution by clinical stage					Number registered (all stages)
EP_O	EP_S	LP_O	LP_S	Met.			EP_O	EP_S	LP_O	LP_S	Met.	
34.6	11.5	23.1	30.8	-	26	0-	41.7	-	16.7	16.7	25.0	12
42.6	9.8	11.5	31.1	4.9	61	15-	70.0	5.0	2.5	22.5	-	40
47.8	9.6	12.2	28.7	1.7	115	25-	63.4	5.2	18.3	12.4	0.7	153
43.5	7.0	16.1	30.4	3.0	299	35-	47.3	5.4	21.7	22.9	2.7	332
32.7	12.4	14.8	37.1	3.0	836	45-	33.2	7.1	25.4	33.0	1.3	702
26.0	10.5	17.1	43.5	2.9	1,797	55-	32.5	5.3	28.9	31.5	1.9	1,027
24.6	9.7	20.2	43.7	1.8	3,259	65-	29.7	6.9	30.5	29.7	3.2	1,030
22.5	7.3	24.8	43.6	1.8	1,788	75-	25.8	5.4	34.3	32.6	1.9	411
20.8	5.2	32.5	39.6	1.9	154	85 and over	24.5	7.5	39.6	26.4	1.9	53
15.0	20.0	17.5	47.5	-	40	Not stated	45.5	-	22.7	31.8	-	22
26.3	**9.5**	**19.9**	**42.1**	**2.2**	**8,375**	**All ages**	**34.1**	**6.1**	**28.0**	**29.7**	**2.2**	**3,782**

Table 47. Cancer of Mouth, Pharynx and Tonsil. Relationship of duration of symptomatic history to clinical stage; 1945-51 registrations

MALES							Duration of symptomatic history (months)	FEMALES						
Percentage distribution by clinical stage						Percentage distribution by stated duration of symptomatic history (all stages)		Percentage distribution by clinical stage						Percentage distribution by stated duration of symptomatic history (all stages)
EP_O	EP_S	LP_O	LP_S	Met.	All stages			EP_O	EP_S	LP_O	LP_S	Met.	All stages	
27.9	12.2	17.8	40.4	1.6	100	13.2	0-	33.5	8.4	26.4	28.9	2.9	100	6.8
23.5	11.0	19.3	44.1	2.2	100	51.3	2-	25.8	7.2	30.2	34.7	2.2	100	39.4
21.6	7.1	22.2	46.6	2.5	100	18.3	6-	27.3	6.8	28.8	34.4	2.7	100	24.1
36.9	6.8	19.4	34.7	2.2	100	17.2	12 and over	50.4	3.3	24.1	20.3	1.9	100	29.7
26.3	**9.5**	**19.9**	**42.1**	**2.2**	**100**	-	**All durations (including "not stated")**	**34.1**	**6.1**	**28.0**	**29.7**	**2.2**	**100**	-
4.5	3.7	4.5	4.2	4.9	4.3	-	Median duration of symptomatic history	3.8	5.4	6.1	5.7	6.5	6.7	-

Table 48. Cancer of Mouth, Pharynx and Tonsil. Number and percentage distribution by treatment in each clinical stage; 1945–51 registrations

Treatment	EP_0		EP_S		LP_0		LP_S		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
	MALES									
RADICAL										
Surgery	225	10.2	18	2.3	46	2.8	43	1.2	3	1.6
Radiotherapy	1,392	63.2	496	62.2	764	45.9	1,259	35.7	54	29.2
Surgery & Radiotherapy	437	19.9	140	17.6	123	7.4	176	5.0	7	3.8
PALLIATIVE										
Surgery	6	0.3	1	0.0	15	0.9	14	0.4	–	–
Radiotherapy	74	3.4	119	14.9	448	26.9	1,458	41.3	76	41.1
Surgery & Radiotherapy	6	0.3	5	0.6	28	1.7	50	1.4	4	2.2
OTHER	1	0.0	–	–	6	0.4	5	0.1	–	–
NONE	60	2.7	18	2.3	235	14.1	522	14.8	41	22.2
ALL CASES	**2,201**	**100**	**797**	**100**	**1,665**	**100**	**3,527**	**100**	**185**	**100**

	FEMALES									
RADICAL										
Surgery	274	21.3	5	2.2	43	4.1	7	0.6	2	2.4
Radiotherapy	605	46.9	134	58.5	398	37.6	383	34.1	16	19.3
Surgery & Radiotherapy	310	24.1	44	19.2	110	10.4	57	5.1	3	3.6
PALLIATIVE										
Surgery	4	0.3	1	0.4	37	3.5	17	1.5	5	6.0
Radiotherapy	43	3.3	34	14.8	242	22.9	449	40.0	27	32.5
Surgery & Radiotherapy	5	0.4	5	2.2	29	2.7	20	1.8	7	8.4
OTHER	–	–	1	0.4	1	0.1	1	0.1	–	–
NONE	48	3.7	5	2.2	199	18.8	188	16.8	23	27.7
ALL CASES	**1,289**	**100**	**229**	**100**	**1,059**	**100**	**1,122**	**100**	**83**	**100**

Table 49. Cancer of Mouth, Pharynx and Tonsil. Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945–51 registrations

Treatment	Clinical stage and age group																	
	EP_0				EP_S				LP_0				LP_S				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over
	MALES																			
RADICAL																				
Surgery	225	29	24	47	18	17	39	44	46	7	20	74	43	9	33	58	3	–	33	67
Radiotherapy	1,387	3	19	78	489	5	23	72	758	4	15	81	1,253	7	20	73	54	11	33	56
Surgery & Radiotherapy	437	23	26	51	140	5	29	66	122	15	25	61	176	4	27	69	7	14	29	57
PALLIATIVE	85	5	20	75	124	6	15	80	491	4	13	83	1,515	3	15	82	80	5	25	70
OTHER and NONE	61	10	18	72	18	–	11	89	241	2	9	89	521	1	11	88	41	7	20	73
ALL CASES	**2,195**	**10**	**21**	**69**	**789**	**5**	**23**	**72**	**1,658**	**5**	**14**	**81**	**3,508**	**4**	**17**	**79**	**185**	**8**	**26**	**66**

	FEMALES																			
RADICAL																				
Surgery	270	38	34	27	5	–	40	60	43	23	42	35	7	14	57	29	2	50	–	50
Radiotherapy	603	10	32	58	134	14	33	53	396	10	31	58	379	12	37	51	16	25	19	56
Surgery & Radiotherapy	307	36	31	34	44	14	41	45	110	17	40	43	57	7	39	54	3	–	33	67
PALLIATIVE	51	12	29	59	40	8	25	68	305	6	31	63	485	9	31	60	39	21	15	64
OTHER and NONE	48	15	38	48	6	–	–	100	200	8	24	69	187	6	33	60	23	–	17	83
ALL CASES	1,279	22	32	45	229	12	32	55	1,054	10	31	59	1,115	10	34	57	83	16	17	67

Table 50. Cancer of Mouth, Pharynx and Tonsil. Number and five-year survival rates*, crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945–48 registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate	
		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected
	MALES														
0–	5	*80*	*80*	–	–	–	3	*33*	*34*	2	*0*	*0*	14	*36*	*36*
15–	12	*75*	*76*	3	*0*	*0*	2	*0*	*0*	4	*25*	*25*	28	43	43
25–	8	*75*	*76*	–	–	–	–	–	–	5	*40*	*40*	18	*44*	*45*
30–	12	*100*	*100*	3	*67*	*67*	1	*0*	*0*	10	*30*	*30*	32	53	54
35–	22	68	69	2	*50*	*51*	5	*0*	*0*	9	*33*	*34*	50	42	43
40–	35	80	82	9	*33*	*34*	11	*45*	*47*	22	*27*	28	106	42	44
45–	65	66	69	20	*45*	*47*	17	*53*	*55*	32	16	16	175	39	41
50–	67	60	64	27	37	40	23	35	37	55	13	14	250	28	30
55–	88	43	48	47	21	24	39	28	32	80	19	21	368	21	24
60–	146	40	48	47	19	23	66	27	33	144	15	17	589	20	24
65–	200	38	50	81	23	31	80	22	29	192	12	16	833	17	23
70–	215	27	41	65	25	37	97	18	27	176	6	9	959	12	18
75–	115	21	40	36	14	26	56	21	41	75	5	10	557	9	18
80–	45	13	36	13	*8*	*21*	31	13	35	27	4	10	250	6	15
85 and over	9	*22*	*95*	1	*0*	*0*	7	*0*	*0*	5	*0*	*0*	57	4	15
All stated ages	**1,044**	**40**	**51**	**354**	**24**	**31**	**438**	**24**	**32**	**838**	**12**	**15**	**4,286**	**18**	**23**

FEMALES

0–	–	–	–	–	–	–	2	*50*	50	1	*0*	*0*	4	*25*	*25*
15–	11	*91*	*92*	1	*100*	*100*	1	*0*	*0*	3	*0*	*0*	17	*65*	*65*
25–	19	*84*	*85*	2	*50*	*50*	4	*25*	*25*	1	*100*	*100*	31	61	62
30–	27	81	82	1	*0*	*0*	9	*56*	*56*	2	*50*	*50*	47	62	62
35–	34	79	80	1	*0*	*0*	11	*45*	*46*	7	*29*	*29*	72	49	49
40–	40	78	79	9	*33*	*34*	12	*58*	*59*	5	*40*	*41*	94	48	49
45–	51	61	62	10	*30*	*31*	23	17	18	17	*24*	*24*	156	29	30
50–	52	46	48	10	*10*	*10*	35	14	15	29	14	14	195	19	20
55–	90	53	57	8	*50*	*53*	42	17	18	26	23	25	248	28	30
60–	76	43	48	14	*50*	*56*	40	25	28	41	12	14	259	22	24
65–	86	59	71	18	*50*	*60*	43	19	22	32	9	11	276	27	32
70–	53	58	79	5	*20*	*27*	32	19	25	19	*21*	*28*	207	27	36
75–	27	37	61	2	*0*	*0*	18	*28*	*46*	19	*16*	*26*	122	19	31
80–	13	*23*	*53*	4	*0*	*0*	10	*20*	*46*	5	*0*	*0*	60	10	23
85 and over	2	*0*	*0*	–	–	–	1	*0*	*0*	–	–	–	13	*0*	*0*
All stated ages	**581**	**58**	**65**	**85**	**35**	**39**	**283**	**23**	**27**	**207**	**17**	**19**	**1,801**	**28**	**32**

* Rates shown in italics are based on 20 or less cases at risk.

Table 51. Cancer of Mouth, Pharynx and Tonsil. Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of symptomatic history (months)	EP_0				EP_S				LP_0				LP_S				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
MALES																								
0-	125	34	141	30	56	25	69	23	49	24	93	14	95	9	244	5	8	*25*	2	*0*	10	*20*	557	15
2-	481	35	507	33	207	23	249	20	217	21	379	13	418	12	942	7	42	10	11	*0*	53	8	2,130	16
6-	162	36	171	36	38	21	49	16	77	22	144	15	194	11	366	7	20	*5*	4	*0*	24	4	754	15
12 and over	219	56	231	54	46	30	56	25	77	32	119	24	98	17	235	8	12	*0*	4	*0*	16	*0*	657	28
Not stated	60	52	61	51	11	*18*	14	*14*	22	18	46	9	33	9	78	5	5	*20*	1	*0*	6	*17*	205	20
All durations	**1,047**	**40**	**1,111**	**39**	**358**	**24**	**437**	**21**	**442**	**23**	**781**	**15**	**838**	**12**	**1,865**	**7**	**87**	**9**	**22**	**0**	**109**	**7**	**4,303**	**18**
FEMALES																								
0-	44	50	47	51	3	*33*	4	*25*	11	*18*	28	11	10	*20*	33	6	2	*0*	1	*0*	3	*0*	115	26
2-	159	47	172	44	38	34	50	34	98	18	197	11	100	15	241	8	9	*11*	6	*0*	15	*7*	675	20
6-	101	45	116	41	23	30	26	27	68	13	116	9	46	13	122	6	9	*0*	2	*0*	11	*0*	391	19
12 and over	254	70	286	68	15	*47*	19	*42*	89	40	133	30	38	29	89	17	8	*0*	2	*0*	10	*0*	517	47
Not stated	27	78	32	69	6	*33*	8	*25*	18	*6*	42	7	14	*7*	32	3	–	–	–	–	–	–	114	25
All durations	**585**	**58**	**633**	**55**	**85**	**35**	**107**	**33**	**284**	**23**	**516**	**15**	**208**	**17**	**517**	**9**	**28**	**4**	**11**	**0**	**39**	**3**	**1,812**	**28**

* Rates shown in italics are based on 20 or less cases at risk.

Table 52. Cancer of Oesophagus. Registration rates per million population and comparative percentage registration rates by clinical stage and age; 1945-51 registrations

Clinical stage	Age Group													
	15-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85 and over
							MALES							
EP_O														
Registration rate	-	-	-	--	1	2	4	7	13	17	21	20	14	12
Comparative registration rate	-	-	-	-	0.9	1.8	3.6	6.3	11.7	15.3	18.9	18.0	12.6	10.8
EP_S, LP_O and LP_S														
Registration rate	0	1	0	2	3	7	17	28	56	92	129	135	80	55
Comparative registration rate	-	0.2	-	0.3	0.5	1.2	2.8	4.6	9.3	15.2	21.3	22.3	13.2	9.1
METASTATIC														
Registration rate	-	0	0	0	0	1	3	5	6	10	10	10	5	7
Comparative registration rate	-	-	-	-	-	1.8	5.3	8.8	10.5	17.5	17.5	17.5	8.8	12.3
							FEMALES							
EP_O														
Registration rate	-	0	1	0	1	2	2	4	6	6	8	7	3	2
Comparative registration rate	-	-	2.4	-	2.4	4.8	4.8	9.5	14.3	14.3	19.0	16.7	7.1	4.8
EP_S, LP_O and LP_S														
Registration rate	0	0	0	2	3	5	9	14	21	29	33	31	14	10
Comparative registration	-	-	-	1.2	1.8	2.9	5.3	8.2	12.3	17.0	19.3	18.1	8.2	5.8
METASTATIC														
Registration rate	-	-	-	0	0	0	1	2	2	2	3	1	2	-
Comparative registration rate	-	-	-	-	-	-	7.7	15.4	15.4	15.4	23.1	7.7	15.4	-

Table 53. Cancer of Oesophagus. **PERSONS**
Relationship of age to clinical stage; 1945–51 registrations

Age Group	Percentage distribution by clinical stage					Number registered (all stages)
	EP_O	EP_S	LP_O	LP_S	Met.	
0–	–	–	–	100.0	–	1
15–	–	–	66.7	33.3	–	3
25–	32.1	3.6	42.9	7.1	14.3	28
35–	10.6	0.7	65.2	15.6	7.8	141
45–	18.9	2.0	55.2	13.8	10.2	509
55–	17.7	1.3	58.2	13.3	9.5	1,213
65–	14.6	1.6	64.8	11.9	7.1	1,812
75–	13.6	0.4	69.7	10.8	5.5	692
85 and over	16.3	–	65.1	11.6	7.0	43
Not stated	35.7	3.6	50.0	7.1	3.6	28
All ages	**15.9**	**1.4**	**62.4**	**12.4**	**7.9**	**4,470**

Table 54. Cancer of Oesophagus. Relationship of duration of symptomatic history to clinical stage; 1945–51 registrations

Duration of symptomatic history (months)	Percentage distribution by clinical stage (persons)				EP_O Percentage of all stages		Percentage distribution by stated duration of symptomatic history (all stages)		
	EP_O	EP_S, LP_O and LP_S	Met.	All stages	Males	Females	Males	Females	Persons
0–	13.6	77.4	9.0	100	13.2	15.5	13.9	8.5	12.3
2–	17.3	75.2	7.5	100	16.4	19.5	56.8	51.5	55.1
6–	15.5	75.4	9.1	100	14.0	18.3	20.2	25.1	21.7
12 and over	13.4	78.9	7.7	100	9.1	19.4	9.1	14.8	10.9
All durations (including "not stated")	**15.9**	**76.2**	**7.9**	**100**	**14.7**	**18.7**	-	-	-
Median duration of symptomatic history	4.2	4.3	4.5	4.3	3.8	5.0	4.0	4.9	4.3

Table 55. Cancer of Oesophagus. **PERSONS**
Number and percentage distribution by treatment in each clinical stage; 1945–51 registrations

Treatment	EP_O		EP_S, LP_O and LP_S		Metastatic	
	Number	Percentage distribution	Number	Percentage distribution	Number	Percentage distribution
RADICAL						
Surgery	264	37.1	275	8.1	25	7.1
Radiotherapy	188	26.4	334	9.8	9	2.5
Surgery & Radiotherapy	26	3.7	31	0.9	3	0.8
PALLIATIVE						
Surgery	56	7.9	506	14.9	69	19.5
Radiotherapy	56	7.9	625	18.4	43	12.2
Surgery & Radiotherapy	6	0.8	100	2.9	8	2.3
OTHER	7	1.0	86	2.5	9	2.5
NONE	108	15.2	1,449	42.5	187	53.0
ALL CASES	**711**	**100**	**3,406**	**100**	**353**	**100**

Table 56. Cancer of Oesophagus **PERSONS**

Number of cases by clinical stage and treatment; also percentage distribution by age in each clinical stage and treatment group; 1945–51 registrations

Treatment	Clinical stage and age group											
	EP_O				EP_S, LP_O and LP_S				Metastatic			
	Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age			Number (all stated ages)	Percentage distribution by age		
		0–	45–	60 and over		0–	45–	60 and over		0–	45–	60 and over
RADICAL												
Surgery	262	6	37	57	272	7	33	60	25	–	44	56
Radiotherapy	183	1	21	78	330	5	26	69	9	–	33	67
Surgery & Radiotherapy	26	8	35	58	31	6	29	65	3	33	33	33
PALLIATIVE	116	1	16	84	1,229	5	22	73	120	6	33	61
OTHER and NONE	114	4	16	81	1,527	2	17	81	195	4	29	68
ALL CASES	**701**	**3**	**26**	**71**	**3,389**	**4**	**21**	**75**	**352**	**4**	**32**	**64**

Table 57. Cancer of Oesophagus. PERSONS

Number and five-year survival rates* crude and corrected, of radically treated cases by clinical stage and age; also of all cases, whether treated or not, by age; 1945–48, registrations

Age Group	Radically treated cases												All cases		
	EP_0			EP_S			LP_0			LP_S					
	Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate		Number	Survival rate	
		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected		Crude	Corrected
0–	–	–	–	–	–	–	–	–	–	1	*0*	*0*	1	*0*	*0*
15–	–	–	–	–	–	–	–	–	–	–	–	–	2	*0*	*0*
25–	2	*50*	*50*	1	*0*	*0*	1	*0*	*0*	–	–	–	12	*8*	*8*
35–	4	*25*	*26*	1	*0*	*0*	14	*7*	*7*	4	*0*	*0*	69	3	3
45–	39	15	16	3	*0*	*0*	38	0	0	9	*11*	*11*	258	3	3
55–	70	10	11	4	*0*	*0*	84	2	3	18	*6*	*7*	616	2	3
65–	81	5	7	11	*0*	*0*	98	3	4	15	*0*	*0*	895	1	2
75–	20	*0*	*0*	–	–	–	27	4	10	4	*0*	*0*	308	0	1
85 and over	–	–	–	–	–	–	1	*0*	*0*	–	–	–	15	*0*	*0*
ALL stated ages	216	9	10	20	*0*	*0*	263	3	4	51	4	4	2,176	2	2

* Rates shown in italics are based on 20 or less cases at risk.

Table 58. Cancer of Oesophagus. PERSONS

Number and five-year crude survival rates* by clinical stage and duration of symptomatic history; 1945-48 registrations

Duration of symptomatic history (months)	EP_0				EP_S				LP_0				LP_S				Metastatic						All cases	
	Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Radically treated		All cases		Treated		Untreated		All cases			
	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate	Number	Survival rate
0-	15	*13*	35	6	1	*0*	2	*0*	22	5	180	1	1	*0*	22	0	7	*0*	15	*0*	22	0	261	2
2-	126	9	187	6	15	*0*	21	0	130	3	713	1	26	4	116	1	40	2	47	0	87	1	1,124	2
6-	49	8	70	6	3	*0*	4	*0*	71	0	269	0	13	*0*	53	0	19	*0*	19	*0*	38	0	434	1
12 and over	18	*11*	22	9	1	*0*	1	*0*	27	7	131	2	7	*14*	35	3	5	*0*	11	*0*	16	*0*	205	3
Not stated	12	*0*	20	*0*	-	-	1	*0*	16	*0*	115	0	4	*0*	23	0	2	*50*	6	*0*	8	*12*	167	1
All durations	**220**	**9**	**334**	**6**	**20**	*0*	**29**	**0**	**266**	**3**	**1,408**	**1**	**51**	**4**	**249**	**1**	**73**	**3**	**98**	**0**	**171**	**1**	**2,191**	**2**

* Rates shown in italics are based on 20 or less cases at risk.

Synoptic Table A.

	Corpus uteri	Ovary	Testis	Penis	Lip			Tongue			Mouth, Pharynx and Tonsil			Oesophagus		
					Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
1945-51 REGISTRATIONS																
Number registered	3,749	4,525	847	1,086	3,724	326	4,050	3,185	1,003	4,188	8,375	3,782	12,157	3,088	1,382	4,470
Mean age at registration	60.1	54.5	40.3	64.5	65.7	66.0	65.7	68.3	64.9	67.5	66.2	59.8	64.2	66.3	63.7	65.5
Staging (percentage distribution)																
Localised growth	58	22	58	43	77	80	77	33	54	38	26	34	29	15	19	16
Regional extension	32	40	26	55	23	19	23	66	46	61	72	64	69	77	75	76
Remote spread	10	38	16	*2*	*0*	*1*	*0*	1	*0*	1	2	2	2	8	7	8
Percentage of cases receiving radical treatment																
Localised growth	97	96	98	90	98	96	98	95	96	95	93	92	93	66	70	67
Regional extension	70	48	78	73	80	65	79	52	59	54	51	49	51	18	21	19
Median duration of symptomatic history																
Localised growth	7.2	4.4	4.9	6.1	6.0	5.7	6.0	3.7	4.5	3.9	4.5	8.8	5.7	3.8	5.0	4.2
Regional extension	8.0	4.5	5.9	5.9	7.9	7.3	7.9	4.0	4.8	4.1	4.1	5.8	4.6	4.1	4.9	4.3
Remote spread	7.6	4.2	6.0	*7.2*	*6.0*	*	*9.0*	4.8	*12.0*	5.0	4.9	6.5	5.2	4.2	5.3	4.5
1945-48 REGISTRATIONS																
Five-year corrected survival rate																
All cases	49	18	52	55	79	73	78	22	38	25	23	32	26	1	3	2
Localised growth - radical treatment	68	57	74	71	88	90	88	47	57	50	51	65	56	7	15	10
Regional extension - radical treatment	46	30	41	60	64	40	63	19	29	21	23	26	24	3	4	4
Remote spread - all cases	10	4	6	*0*	*12*	*0*	*9*	0	*0*	0	9	4	8	1	3	1
Five-year crude survival rate																
All cases - duration under 6 months	41	16	53	42	58	57	58	16	34	20	16	21	17	1	3	2
- duration over 6 months	47	20	48	44	61	60	61	18	28	20	21	35	27	0	4	2
Localised growth - radical treatment																
- duration under 6 months	56	53	75	50	64	70	64	33	49	38	34	47	38	8	12	9
- duration over 6 months	64	58	67	59	71	76	71	41	43	42	46	63	55	0	19	9
Regional extension - radical treatment																
- duration under 6 months	39	24	37	46	46	*25*	45	14	25	16	17	20	18	2	5	3
- duration over 6 months	43	37	41	48	44	*38*	44	14	22	16	19	27	22	3	2	2

NOTE: Figures shown in italics are based on 20 or less cases at risk.

* 1 case only (symptomatic history duration of 12-17 months).

Synoptic Table B.

	Breast	Cervix Uteri	Prostate	Stomach			Intestine (excluding rectum)			Rectum			Lung			Epithelioma of Skin		
				Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons	Males	Females	Persons
1945-49 REGISTRATIONS																		
Number registered	21,508	11,618	3,190	6,312	3,581	9,893	3,812	4,118	7,930	5,482	3,290	8,772	11,545	1,663	13,208	5,605	2,971	8,576
Mean age at registration	58.1	55.4	69.5	60.3	61.1	60.6	63.1	61.8	62.4	63.5	61.1	62.6	56.2	56.3	56.2	65.2	65.6	65.3
Staging (percentage distribution)																		
Localised growth	30	46	34	13	12	13	27	31	29	33	34	33	11	8	11	79	77	78
Regional extension	60	47	43	53	52	53	48	45	46	51	49	50	65	65	65	21	22	21
Remote spread	10	8	23	34	35	34	25	24	24	17	17	17	24	27	24	1	1	1
Percentage of cases receiving radical treatment																		
Localised growth	95	98	57	76	71	74	83	85	84	84	83	84	67	54	65	97	97	97
Regional extension	76	71	18	20	19	20	28	28	28	31	33	32	16	14	16	78	73	76
Median duration of symptomatic history																		
Localised growth	4.1	5.1	5.9	6.3	6.5	6.4	3.6	4.0	3.8	5.3	6.4	5.7	6.0	6.4	6.0	6.0	7.3	6.4
Regional extension	6.9	6.3	5.6	5.6	5.9	5.7	3.7	3.9	3.8	5.7	6.5	6.0	5.6	5.8	5.6	11.9	22.7	14.5
Remote spread	11.4	6.1	5.6	4.8	4.7	4.8	3.9	4.5	4.4	4.9	5.6	5.2	4.5	4.9	4.5	10.5	13.7	11.6
1945-47 REGISTRATIONS																		
Five-year corrected survival rate																		
All cases	37	35	24	6	4	5	15	18	17	16	21	18	2	3	2	78	77	78
Localised growth-radical treatment	67	51	44	34	25	31	45	46	46	42	54	47	14	8	13	87	88	87
Regional extension - radical treatment	35	31	24	17	6	13	28	33	30	27	33	30	3	11	4	61	59	60
Remote spread - all cases	6	15	12	1	1	1	2	4	3	4	3	3	0	1	0	*22*	*35*	27
Five-year crude survival rate																		
All cases - duration under 6 months	38	34	18	3	3	3	13	15	14	13	16	14	1	2	2	64	73	67
- duration over 6 months	28	31	16	7	4	6	12	19	15	14	21	17	2	3	2	52	53	52
Localised growth - radical treatment																		
- duration under 6 months	61	47	32	26	17	23	38	37	38	33	45	37	17	*8*	16	69	77	72
- duration over 6 months	59	46	31	34	27	32	38	46	42	39	50	43	9	*7*	8	60	65	62
Regional extension - radical treatment																		
- duration under 6 months	33	27	20	10	6	9	21	26	23	24	20	22	2	9	2	50	62	53
- duration over 6 months	30	29	17	18	5	14	21	38	29	22	36	28	*4	12	5	42	38	40

NOTE: Figures shown in italics are based on 20 or less cases at risk.

Appendix Table. Condition at end of each year up to five years by site, sex, clinical stage and treatment; 1945-48 registrations.

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Corpus Uteri																	
EP_0	Radical	811	712	93	6	634	170	7	585	217	9	540	255	16	497	287	27
	Other	15	6	9	–	3	12	–	2	13	–	1	14	–	1	14	–
	None	14	7	5	2	6	6	2	4	8	2	3	8	3	3	8	3
	TOTAL	**840**	**725**	**107**	**8**	**643**	**188**	**9**	**591**	**238**	**11**	**544**	**277**	**19**	**501**	**309**	**30**
EP_S	Radical	25	20	5	–	18	7	–	17	8	–	15	10	–	13	11	1
	Other	1	1	–	–	–	1	–	–	1	–	–	1	–	–	1	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**27**	**21**	**6**	**–**	**18**	**9**	**–**	**17**	**10**	**–**	**15**	**12**	**–**	**13**	**13**	**1**
Met (EP)	Radical	11	6	5	–	6	5	–	6	5	–	5	6	–	4	7	–
	Other	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**12**	**6**	**6**	**–**	**6**	**6**	**–**	**6**	**6**	**–**	**5**	**7**	**–**	**4**	**8**	**–**
LP_0	Radical	327	247	78	2	181	144	2	160	165	2	146	179	2	131	194	2
	Other	67	27	40	–	13	54	–	8	59	–	7	60	–	5	62	–
	None	61	10	46	5	7	49	5	6	50	5	3	53	5	3	53	5
	TOTAL	**455**	**284**	**164**	**7**	**201**	**247**	**7**	**174**	**274**	**7**	**156**	**292**	**7**	**139**	**309**	**7**
LP_S	Radical	21	17	3	1	15	5	1	14	6	1	14	6	1	13	7	1
	Other	7	1	6	–	1	6	–	1	6	–	1	6	–	1	6	–
	None	18	1	17	–	–	18	–	–	18	–	–	18	–	–	18	–
	TOTAL	**46**	**19**	**26**	**1**	**16**	**29**	**1**	**15**	**30**	**1**	**15**	**30**	**1**	**14**	**31**	**1**
Met (LP)	Radical	52	26	26	–	18	34	–	13	39	–	12	40	–	9	42	1
	Other	46	15	31	–	7	39	–	4	41	1	4	41	1	4	41	1
	None	61	1	59	1	–	60	1	–	60	1	–	60	1	–	60	1
	TOTAL	**159**	**42**	**116**	**1**	**25**	**133**	**1**	**17**	**140**	**2**	**16**	**141**	**2**	**13**	**143**	**3**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Ovary																	
EP_0	Radical	324	257	62	5	231	88	5	207	109	8	184	131	9	173	139	12
	Other	10	5	5	-	5	5	-	5	5	-	5	5	2	2	6	2
	None	6	1	5	-	1	5	-	-	5	1	-	5	1	-	5	1
	TOTAL	**340**	**263**	**72**	**5**	**237**	**98**	**5**	**212**	**119**	**9**	**187**	**141**	**12**	**175**	**150**	**15**
EP_S	Radical	12	10	1	1	6	5	1	5	6	1	4	7	1	4	7	1
	Other	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	TOTAL	**13**	**10**	**2**	**1**	**6**	**6**	**1**	**5**	**7**	**1**	**4**	**8**	**1**	**4**	**8**	**1**
Met (EP)	Radical	19	11	8	-	8	11	-	5	14	-	4	15	-	4	15	-
	Other	3	2	1	-	1	2	-	1	2	-	1	2	-	-	3	-
	None	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	TOTAL	**23**	**13**	**10**	**-**	**9**	**14**	**-**	**6**	**17**	**-**	**5**	**18**	**-**	**4**	**19**	**-**
LP_0	Radical	255	138	114	3	106	146	3	97	155	3	84	166	5	76	171	8
	Other	126	32	93	1	21	104	1	16	109	1	11	112	3	8	114	4
	None	204	22	179	3	12	189	3	10	191	3	8	193	3	6	195	3
	TOTAL	**585**	**192**	**386**	**7**	**139**	**439**	**7**	**123**	**455**	**7**	**103**	**471**	**11**	**90**	**480**	**15**
LP_S	Radical	43	20	23	-	11	32	-	10	33	-	9	34	-	8	35	-
	Other	38	5	33	-	2	36	-	2	36	-	1	37	-	1	37	-
	None	43	6	36	1	3	39	1	-	42	1	-	42	1	-	42	1
	TOTAL	**124**	**31**	**92**	**1**	**16**	**107**	**1**	**12**	**111**	**1**	**10**	**113**	**1**	**9**	**114**	**1**
Met(LP)	Radical	137	39	96	2	26	109	2	19	116	2	16	119	2	13	122	2
	Other	190	32	158	-	13	176	1	13	176	1	10	179	1	10	179	1
	None	427	22	401	4	7	415	5	6	416	5	4	418	5	4	418	5
	TOTAL	**754**	**93**	**655**	**6**	**46**	**700**	**8**	**38**	**708**	**8**	**30**	**716**	**8**	**27**	**719**	**8**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Testis																	
EP'_0	Radical	195	169	23	3	151	40	4	146	43	6	142	45	8	139	47	9
	Other	1	1	–	–	1	–	–	1	–	–	1	–	–	1	–	–
	None	1	1	–	–	1	–	–	1	–	–	1	–	–	1	–	–
	TOTAL	**197**	**171**	**23**	**3**	**153**	**40**	**4**	**148**	**43**	**6**	**144**	**45**	**8**	**141**	**47**	**9**
EP_s	Radical	15	9	6	–	6	9	–	6	9	–	6	9	–	6	9	–
	Other	2	–	2	–	–	2	–	–	2	–	–	2	–	–	2	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**17**	**9**	**8**	**–**	**6**	**11**	**–**	**6**	**11**	**–**	**6**	**11**	**–**	**6**	**11**	**–**
Met (EP)	Radical	5	–	5	–	–	5	–	–	5	–	–	5	–	–	5	–
	Other	3	–	3	–	–	3	–	–	3	–	–	3	–	–	3	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**9**	**–**	**9**	**–**	**–**	**9**	**–**	**–**	**9**	**–**	**–**	**9**	**–**	**–**	**9**	**–**
LP_0	Radical	31	18	13	–	15	16	–	14	17	–	14	17	–	14	17	–
	Other	5	2	3	–	2	3	–	2	3	–	2	3	–	2	3	–
	None	2	–	2	–	–	2	–	–	2	–	–	2	–	–	2	–
	TOTAL	**38**	**20**	**18**	**–**	**17**	**21**	**–**	**16**	**22**	**–**	**16**	**22**	**–**	**16**	**22**	**–**
LP_s	Radical	22	13	9	–	10	12	–	9	13	–	6	14	2	6	14	2
	Other	10	5	5	–	4	6	–	3	7	–	2	8	–	2	8	–
	None	2	–	2	–	–	2	–	–	2	–	–	2	–	–	2	–
	TOTAL	**34**	**18**	**16**	**–**	**14**	**20**	**–**	**12**	**22**	**–**	**8**	**24**	**2**	**8**	**24**	**2**
Met (LP)	Radical	16	6	10	–	6	10	–	6	10	–	4	12	–	4	12	–
	Other	23	2	21	–	–	23	–	–	23	–	–	23	–	–	23	–
	None	18	–	17	1	–	17	1	–	17	1	–	17	1	–	17	1
	TOTAL	**57**	**8**	**48**	**1**	**6**	**50**	**1**	**6**	**50**	**1**	**4**	**52**	**1**	**4**	**52**	**1**

Appendix Table (Contd.)

Clinical stage	Treat-ment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Penis																	
EP_o	Radical	186	166	18	2	146	37	3	126	55	5	112	66	8	104	73	9
	Other	1	–	–	1	–	–	1	–	–	1	–	–	1	–	–	1
	None	20	10	1	9	9	2	9	7	4	9	6	5	9	5	6	9
	TOTAL	**207**	**176**	**19**	**12**	**155**	**39**	**13**	**133**	**59**	**15**	**118**	**71**	**18**	**109**	**79**	**19**
EP_s	Radical	76	62	13	1	51	24	1	44	31	1	43	32	1	40	35	1
	Other	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	None	2	1	1	–	1	1	–	1	1	–	1	1	–	1	1	–
	TOTAL	**79**	**63**	**15**	**1**	**52**	**26**	**1**	**45**	**33**	**1**	**44**	**34**	**1**	**41**	**37**	**1**
Met (EP)	Radical	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
LP_o	Radical	42	38	4	–	31	11	–	27	15	–	26	16	–	22	19	1
	Other	10	2	7	1	1	8	1	–	9	1	–	9	1	–	9	1
	None	9	3	5	1	1	7	1	1	7	1	1	7	1	–	8	1
	TOTAL	**61**	**43**	**16**	**2**	**33**	**26**	**2**	**28**	**31**	**2**	**27**	**32**	**2**	**22**	**36**	**3**
LP_s	Radical	129	97	32	–	80	48	1	66	62	1	62	64	3	55	70	4
	Other	25	12	13	–	6	19	–	6	19	–	5	20	–	4	21	–
	None	22	8	13	1	3	18	1	3	18	1	1	19	2	1	19	2
	TOTAL	**176**	**117**	**58**	**1**	**89**	**85**	**2**	**75**	**99**	**2**	**68**	**103**	**5**	**60**	**110**	**6**
Met (LP)	Radical	5	3	2	–	1	4	–	1	4	–	1	4	–	–	5	–
	Other	4	–	4	–	–	4	–	–	4	–	–	4	–	–	4	–
	None	5	–	5	–	–	5	–	–	5	–	–	5	–	–	5	–
	TOTAL	**14**	**3**	**11**	**–**	**1**	**13**	**–**	**1**	**13**	**–**	**1**	**13**	**–**	**–**	**14**	**–**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Lip																	
MALES																	
EP_o	Radical	1,344	1,243	91	10	1,134	199	11	1,051	267	26	979	324	41	899	383	62
	Other	9	6	3	–	6	3	–	5	4	–	5	4	–	4	5	–
	None	18	10	5	3	9	6	3	8	7	3	6	9	3	4	11	3
	TOTAL	**1,371**	**1,259**	**99**	**13**	**1,149**	**208**	**14**	**1,064**	**278**	**29**	**990**	**337**	**44**	**907**	**399**	**65**
EP_s	Radical	142	118	24	–	98	41	3	91	48	3	81	58	3	75	62	5
	Other	14	7	7	–	6	8	–	5	9	–	5	9	–	4	10	–
	None	2	1	1	–	1	1	–	1	1	–	1	1	–	1	1	–
	TOTAL	**158**	**126**	**32**	**–**	**105**	**50**	**3**	**97**	**58**	**3**	**87**	**68**	**3**	**80**	**73**	**5**
Met (EP)	Radical	1	1	–	–	1	–	–	1	–	–	1	–	–	1	–	–
	Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**1**	**1**	**–**	**–**	**1**	**–**	**–**	**1**	**–**	**–**	**1**	**–**	**–**	**1**	**–**	**–**
LP_o	Radical	89	74	13	2	64	23	2	54	33	2	48	37	4	44	41	4
	Other	13	7	6	–	4	9	–	3	10	–	3	10	–	3	10	–
	None	3	–	3	–	–	3	–	–	3	–	–	3	–	–	3	–
	TOTAL	**105**	**81**	**22**	**2**	**68**	**35**	**2**	**57**	**46**	**2**	**51**	**50**	**4**	**47**	**54**	**4**
LP_s	Radical	121	80	40	1	59	60	2	50	69	2	43	76	2	40	79	2
	Other	49	7	42	–	1	47	1	1	47	1	1	47	1	1	47	1
	None	11	3	8	–	–	11	–	–	11	–	–	11	–	–	11	–
	TOTAL	**181**	**90**	**90**	**1**	**60**	**118**	**3**	**51**	**127**	**3**	**44**	**134**	**3**	**41**	**137**	**3**
Met (LP)	Radical	5	4	1	–	2	3	–	–	5	–	–	5	–	–	5	–
	Other	2	–	2	–	–	2	–	–	2	–	–	2	–	–	2	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**8**	**4**	**4**	**–**	**2**	**6**	**–**	**–**	**8**	**–**	**–**	**8**	**–**	**–**	**8**	**–**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
								Lip									
								FEMALES									
EP_o	Radical	109	104	5	–	101	7	1	90	18	1	85	23	1	80	27	2
	Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	None	3	1	–	2	–	1	2	–	1	2	–	1	2	–	1	2
	TOTAL	**112**	**105**	**5**	**2**	**101**	**8**	**3**	**90**	**19**	**3**	**85**	**24**	**3**	**80**	**28**	**4**
EP_s	Radical	9	6	3	–	5	4	–	5	4	–	5	4	–	5	4	–
	Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**9**	**6**	**3**	**–**	**5**	**4**	**–**	**5**	**4**	**–**	**5**	**4**	**–**	**5**	**4**	**–**
Met (EP)	Radical	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	None	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	TOTAL	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**	**–**
LP_o	Radical	12	9	3	–	5	7	–	5	7	–	3	9	–	2	9	1
	Other	1	1	–	–	–	1	–	–	1	–	–	1	–	–	1	–
	None	3	1	2	–	1	2	–	1	2	–	–	3	–	–	3	–
	TOTAL	**16**	**11**	**5**	**–**	**6**	**10**	**–**	**6**	**10**	**–**	**3**	**13**	**–**	**2**	**13**	**1**
LP_s	Radical	3	2	1	–	2	1	–	2	1	–	1	1	1	1	1	1
	Other	5	1	4	–	–	5	–	–	5	–	–	5	–	–	5	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**9**	**3**	**6**	**–**	**2**	**7**	**–**	**2**	**7**	**–**	**1**	**7**	**1**	**1**	**7**	**1**
Met (LP)	Radical	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
	Other	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**2**	**–**	**2**	**–**	**–**	**2**	**–**	**–**	**2**	**–**	**–**	**2**	**–**	**–**	**2**	**–**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Tongue																	
MALES																	
EP_0	Radical	535	408	126	1	297	235	3	254	278	3	221	308	6	191	335	9
	Other	7	3	4	-	1	6	-	1	6	-	1	6	-	-	7	-
	None	13	2	8	3	1	9	3	1	9	3	1	9	3	1	9	3
	TOTAL	**555**	**413**	**138**	**4**	**299**	**250**	**6**	**256**	**293**	**6**	**223**	**323**	**9**	**192**	**351**	**12**
EP_S	Radical	173	92	80	1	60	112	1	45	127	1	39	133	1	32	140	1
	Other	29	14	15	-	8	21	-	3	26	-	2	27	-	2	27	-
	None	4	-	4	-	-	4	-	-	4	-	-	4	-	-	4	-
	TOTAL	**206**	**106**	**99**	**1**	**68**	**137**	**1**	**48**	**157**	**1**	**41**	**164**	**1**	**34**	**171**	**1**
Met (EP)	Radical	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	TOTAL	**1**	**-**	**1**	**-**	**-**	**1**	**-**	**-**	**1**	**-**	**-**	**1**	**-**	**-**	**1**	**-**
LP_0	Radical	154	76	77	1	43	110	1	35	118	1	30	123	1	22	131	1
	Other	63	20	43	-	9	54	-	6	57	-	2	61	-	2	61	-
	None	37	3	31	3	-	34	3	-	34	3	-	34	3	-	34	3
	TOTAL	**254**	**99**	**151**	**4**	**52**	**198**	**4**	**41**	**209**	**4**	**32**	**218**	**4**	**24**	**226**	**4**
LP_S	Radical	293	124	165	4	66	223	4	48	241	4	36	252	5	31	257	5
	Other	267	58	209	-	16	250	1	10	256	1	6	260	1	5	261	1
	None	153	13	127	13	2	138	13	1	139	13	1	139	13	1	139	13
	TOTAL	**713**	**195**	**501**	**17**	**84**	**611**	**18**	**59**	**636**	**18**	**43**	**651**	**19**	**37**	**657**	**19**
Met (LP)	Radical	4	3	1	-	3	1	-	1	3	-	-	4	-	-	4	-
	Other	8	2	6	-	-	8	-	-	8	-	-	8	-	-	8	-
	None	8	-	8	-	-	8	-	-	8	-	-	8	-	-	8	-
	TOTAL	**20**	**5**	**15**	**-**	**3**	**17**	**-**	**1**	**19**	**-**	**-**	**20**	**-**	**-**	**20**	**-**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Tongue																	
FEMALES																	
EP_O	Radical	241	190	51	--	146	95	-	133	107	1	120	118	3	113	123	5
	Other	3	2	1	-	2	1	-	2	1	-	2	1	-	-	2	1
	None	7	6	1	-	4	3	-	2	4	1	1	4	2	1	4	2
	TOTAL	**251**	**198**	**53**	**-**	**152**	**99**	**-**	**137**	**112**	**2**	**123**	**123**	**5**	**114**	**129**	**8**
EP_S	Radical	46	26	20	-	21	25	-	17	29	-	15	31	-	15	31	-
	Other	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	None	5	-	3	2	-	3	2	-	3	2	-	3	2	-	3	2
	TOTAL	**52**	**26**	**24**	**2**	**21**	**29**	**2**	**17**	**33**	**2**	**15**	**35**	**2**	**15**	**35**	**2**
Met (EP)	Radical	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	TOTAL	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
LP_O	Radical	35	23	12	-	13	22	-	13	22	-	11	24	-	10	25	-
	Other	10	2	8	-	2	8	-	2	8	-	2	8	-	1	9	-
	None	8	2	6	-	1	7	-	-	8	-	-	8	-	-	8	-
	TOTAL	**53**	**27**	**26**	**-**	**16**	**37**	**-**	**15**	**38**	**-**	**13**	**40**	**-**	**11**	**42**	**-**
LP_S	Radical	50	23	27	-	13	37	-	9	41	-	7	43	-	7	43	-
	Other	40	4	35	1	2	37	1	2	37	1	2	37	1	2	37	1
	None	30	7	21	2	-	28	2	-	28	2	-	28	2	-	28	2
	TOTAL	**120**	**34**	**83**	**3**	**15**	**102**	**3**	**11**	**106**	**3**	**9**	**108**	**3**	**9**	**103**	**3**
Met (LP)	Radical	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	Other	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	TOTAL	**2**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Mouth, Pharynx and Tonsil																	
MALES																	
EP_o	Radical	1,047	831	207	9	635	397	15	532	497	18	464	561	22	420	598	29
	Other	33	15	17	1	8	24	1	5	27	1	4	28	1	3	29	1
	None	31	13	10	8	10	11	10	9	12	10	5	15	11	5	15	11
	TOTAL	**1,111**	**859**	**234**	**18**	**653**	**432**	**26**	**546**	**536**	**29**	**473**	**604**	**34**	**428**	**642**	**41**
EP_s	Radical	358	219	136	3	142	212	4	110	244	4	105	249	4	86	268	4
	Other	69	31	38	-	21	48	-	10	59	-	7	62	-	4	65	-
	None	10	1	9	-	1	9	-	-	10	-	-	10	-	-	10	-
	TOTAL	**437**	**251**	**183**	**3**	**164**	**269**	**4**	**120**	**313**	**4**	**112**	**321**	**4**	**90**	**343**	**4**
Met (EP)	Radical	2	1	1	-	-	2	-	-	2	-	-	2	-	-	2	-
	Other	5	3	2	-	1	4	-	-	5	-	-	5	-	-	5	-
	None	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	TOTAL	**7**	**4**	**3**	**-**	**1**	**6**	**-**	**-**	**7**	**-**	**-**	**7**	**-**	**-**	**7**	**-**
LP_o	Radical	442	268	172	2	188	250	4	148	289	5	127	310	5	103	331	8
	Other	214	61	153	-	32	182	-	19	195	-	13	201	-	13	201	-
	None	125	16	95	14	2	109	14	2	109	14	1	110	14	1	110	14
	TOTAL	**781**	**345**	**420**	**16**	**222**	**541**	**18**	**169**	**593**	**19**	**141**	**621**	**19**	**117**	**642**	**22**
LP_s	Radical	838	390	439	9	204	625	9	154	674	10	124	702	12	102	723	13
	Other	730	177	551	2	52	676	2	33	695	2	22	706	2	20	708	2
	None	297	17	258	22	2	273	22	2	273	22	2	273	22	2	273	22
	TOTAL	**1,865**	**584**	**1,248**	**33**	**258**	**1,574**	**33**	**189**	**1,642**	**34**	**148**	**1,681**	**36**	**124**	**1,704**	**37**
Met (LP)	Radical	36	16	20	-	10	26	-	7	29	-	7	29	-	6	29	1
	Other	44	9	34	1	4	39	1	2	41	1	2	41	1	2	41	1
	None	22	1	19	2	-	20	2	-	20	2	-	20	2	-	20	2
	TOTAL	**102**	**26**	**73**	**3**	**14**	**85**	**3**	**9**	**90**	**3**	**9**	**90**	**3**	**8**	**90**	**4**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Mouth, Pharynx and Tonsil																	
FEMALES																	
EP_O	Radical	585	458	119	8	409	167	9	376	196	13	361	201	23	340	218	27
	Other	24	9	15	-	5	19	-	5	19	-	5	19	-	4	20	-
	None	24	9	12	3	8	13	3	6	15	3	6	15	3	6	15	3
	TOTAL	**633**	**476**	**146**	**11**	**422**	**199**	**12**	**387**	**230**	**16**	**372**	**235**	**26**	**350**	**253**	**30**
EP_S	Radical	85	65	20	-	48	37	-	40	45	-	32	52	1	30	54	1
	Other	19	8	11	-	6	13	-	5	14	-	4	15	-	4	15	-
	None	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	TOTAL	**107**	**74**	**32**	**1**	**55**	**51**	**1**	**46**	**60**	**1**	**37**	**68**	**2**	**35**	**70**	**2**
Met (EP)	Radical	1	1	-	-	-	1	-	-	1	-	-	1	-	-	1	-
	Other	4	2	2	-	1	3	-	1	3	-	1	3	-	1	3	-
	None	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	TOTAL	**6**	**3**	**3**	**-**	**1**	**5**	**-**	**1**	**5**	**-**	**1**	**5**	**-**	**1**	**5**	**-**
LP_O	Radical	284	143	139	2	99	183	2	79	202	3	70	210	4	66	214	4
	Other	130	34	95	1	18	111	1	15	114	1	12	117	1	10	119	1
	None	102	9	87	6	5	91	6	4	92	6	3	93	6	3	93	6
	TOTAL	**516**	**186**	**321**	**9**	**122**	**385**	**9**	**98**	**408**	**10**	**85**	**420**	**11**	**79**	**426**	**11**
LP_S	Radical	208	93	115	-	51	157	-	39	169	-	37	171	-	35	172	1
	Other	224	41	183	-	17	207	-	13	211	-	9	215	-	9	215	-
	None	85	3	70	12	1	72	12	1	72	12	1	72	12	1	72	12
	TOTAL	**517**	**137**	**368**	**12**	**69**	**436**	**12**	**53**	**452**	**12**	**47**	**458**	**12**	**45**	**459**	**13**
Met (LP)	Radical	8	2	6	-	2	6	-	2	6	-	-	8	-	-	8	-
	Other	15	2	13	-	2	13	-	-	14	1	-	14	1	-	14	1
	None	10	-	9	1	-	9	1	-	9	1	-	9	1	-	9	1
	TOTAL	**33**	**4**	**28**	**1**	**4**	**28**	**1**	**2**	**29**	**2**	**-**	**31**	**2**	**-**	**31**	**2**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Oesophagus MALES																	
EP_o	Radical	143	52	91	–	17	126	–	11	132	–	9	133	1	8	134	1
	Other	47	7	40	–	2	45	–	–	47	–	–	47	–	–	47	–
	None	30	3	27	–	–	30	–	–	30	–	–	30	–	–	30	–
	TOTAL	**220**	**62**	**158**	**–**	**19**	**201**	**–**	**11**	**209**	**–**	**9**	**210**	**1**	**8**	**211**	**1**
EP_s	Radical	15	3	12	–	2	13	–	1	14	–	1	14	–	–	15	–
	Other	6	–	6	–	–	6	–	–	6	–	–	6	–	–	6	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**22**	**3**	**19**	**–**	**2**	**20**	**–**	**1**	**21**	**–**	**1**	**21**	**–**	**–**	**22**	**–**
Met (EP)	Radical	1	1	–	–	–	1	–	–	1	–	–	1	–	–	1	–
	Other	3	1	2	–	1	2	–	–	3	–	–	3	–	–	3	–
	None	1	–	1	–	–	1	–	–	1	–	–	1	–	–	1	–
	TOTAL	**5**	**2**	**3**	**–**	**1**	**4**	**–**	**–**	**5**	**–**	**–**	**5**	**–**	**–**	**5**	**–**
LP_o	Radical	173	28	145	–	13	160	–	5	168	–	4	169	–	4	169	–
	Other	399	29	370	–	8	391	–	3	396	–	3	396	–	3	396	–
	None	426	17	386	23	5	398	23	2	401	23	2	401	23	–	403	23
	TOTAL	**998**	**74**	**901**	**23**	**26**	**949**	**23**	**10**	**965**	**23**	**9**	**966**	**23**	**7**	**968**	**23**
LP_s	Radical	34	5	29	–	2	32	–	1	33	–	1	33	–	1	33	–
	Other	61	3	57	1	–	60	1	–	60	1	–	60	1	–	60	1
	None	74	5	67	2	–	72	2	–	72	2	–	72	2	–	72	2
	TOTAL	**169**	**13**	**153**	**3**	**2**	**164**	**3**	**1**	**165**	**3**	**1**	**165**	**3**	**1**	**165**	**3**
Met (LP)	Radical	9	1	8	–	1	8	–	1	8	–	1	8	–	1	8	–
	Other	43	–	43	–	–	43	–	–	43	–	–	43	–	–	43	–
	None	71	1	70	–	–	71	–	–	71	–	–	71	–	–	71	–
	TOTAL	**123**	**2**	**121**	**–**	**1**	**122**	**–**	**1**	**122**	**–**	**1**	**122**	**–**	**1**	**122**	**–**

Appendix Table (Contd.)

Clinical stage	Treatment	Total registrations	1st year			2nd year			3rd year			4th year			5th year		
			Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced	Alive	Dead	Not traced
Oesophagus FEMALES																	
EP_o	Radical	77	30	47	-	22	55	-	13	64	-	12	65	-	11	66	-
	Other	27	3	23	1	1	25	1	1	25	1	1	25	1	1	25	1
	None	10	-	10	-	-	10	-	-	10	-	-	10	-	-	10	-
	TOTAL	**114**	**33**	**80**	**1**	**23**	**90**	**1**	**14**	**99**	**1**	**13**	**100**	**1**	**12**	**101**	**1**
EP_s	Radical	5	-	5	-	-	5	-	-	5	-	-	5	-	-	5	-
	Other	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	None	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	TOTAL	**7**	**-**	**7**	**-**	**-**	**7**	**-**	**-**	**7**	**-**	**-**	**7**	**-**	**-**	**7**	**-**
Met (EP)	Radical	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
	Other	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	None	1	-	1	-	-	1	-	-	1	-	-	1	-	-	1	-
	TOTAL	**2**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**	**-**	**2**	**-**
LP_o	Radical	93	14	79	-	5	88	-	5	88	-	4	89	-	3	90	-
	Other	161	13	148	-	4	157	-	3	158	-	3	158	-	1	160	-
	None	156	5	144	7	1	148	7	1	148	7	1	148	7	1	148	7
	TOTAL	**410**	**32**	**371**	**7**	**10**	**393**	**7**	**9**	**394**	**7**	**8**	**395**	**7**	**5**	**398**	**7**
LP_s	Radical	17	4	13	-	1	16	-	1	16	-	1	16	-	1	16	-
	Other	36	3	33	-	-	36	-	-	36	-	-	36	-	-	36	-
	None	27	-	24	3	-	24	3	-	24	3	-	24	3	-	24	3
	TOTAL	**80**	**7**	**70**	**3**	**1**	**76**	**3**	**1**	**76**	**3**	**1**	**76**	**3**	**1**	**76**	**3**
Met (LP)	Radical	5	1	4	-	1	4	-	1	4	-	1	4	-	1	4	-
	Other	11	1	10	-	-	11	-	-	11	-	-	11	-	-	11	-
	None	25	-	24	1	-	24	1	-	24	1	-	24	1	-	24	1
	TOTAL	**41**	**2**	**38**	**1**	**1**	**39**	**1**	**1**	**39**	**1**	**1**	**39**	**1**	**1**	**39**	**1**

GENERAL REGISTER OFFICE

STUDIES ON MEDICAL AND POPULATION SUBJECTS

Study No. 12

The Survey of Sickness 1943 to 1952

This study gives an account of the origin and scope of the Survey of Sickness, describes its methods and makes a considered appraisal of its contribution, actual and potential, to morbidity statistics in this country. The study also gives some account of social surveys in general and of sickness surveys of various kinds in other countries.

Price 4s. 0d. *net* *By Post* 4s. 5d.

Study No. 13

Cancer Statistics for England and Wales 1901–1955

A summary of data relating to mortality and morbidity

Information about mortality from cancer during the twentieth century is brought together in this study, which contains, in addition, some information on the survival of cancer patients who have been to hospital.

Price 5s. 6d. *net* *By Post* 5s. 11d.

Obtainable from

HER MAJESTY'S STATIONERY OFFICE

at the addresses shown on cover page iv
or through any bookseller

© *Crown copyright 1958*

Printed and published by
HER MAJESTY'S STATIONERY OFFICE

To be purchased from
York House, Kingsway, London W.C.2
423 Oxford Street, London W.1
13A Castle Street, Edinburgh 2
109 St Mary Street, Cardiff
39 King Street, Manchester 2
Tower Lane, Bristol 1
2 Edmund Street, Birmingham 3
80 Chichester Street, Belfast
or through any bookseller

Printed in Great Britain



S.O. Code No. 70-765-0-53